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SECTION I  
 
INTRODUCTION 
 
Hypotheses 
 
The thesis aims to explore the role of gene variation on asthma control in children and 
young adults. In order to achieve this, I have focused on the role of two common gene 
mutations that could have significant functional roles in this context. I have performed 
further studies to explore the biological role of one of the two mutations. The thesis 
explores the following three key hypotheses:   
 
1. There is an association between the presence of the Arg16 variation on the β2 
adrenergic receptor gene (ADRB2) and the daily use of any inhaled β2-agonist (as 
required salbutamol and/or regular salmeterol) on the risk of asthma exacerbations. 
2. There is increased risk of asthma exacerbations in the children and young adults 
with filaggrin null mutations.  
3. The barrier function of epithelia in the skin and gastrointestinal tract is reduced in 
asthmatic children with filaggrin mutations.  
15 
 
Objectives 
 
1. To create a database containing information on genotype and clinical phenotype in 
children with asthma 
2. To test the overall effect of the Arg16 allele on the β2 adrenergic receptor gene 
(ADRB2) on the individual measures of asthma exacerbations and on the overall risk 
of exacerbations. 
3. To test the effect of the genotype variations of ADRB2 on the daily use of any β2-
agonists  
4. To study the association between R501X and 2282del4 alleles of filaggrin null 
mutations and the risk of asthma exacerbations  
5. To explore the distribution and function of filaggrin protein in the human skin and 
intestine, in order to help identify the primary site of allergen entry in humans. 
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Summary 
 
1. I have described a population of children and young adults with asthma in primary 
and secondary care, in terms of relevant history, medication use and exacerbations. 
2. My thesis presents observations reported for the first time that asthmatic children 
and young adults homozygous for the Arg16 allele on the β2 adrenergic receptor 
gene (ADRB2), on frequent doses of on demand short-acting β2-agonists are at 
greater risk of asthma exacerbations.  
3. I have shown an increase in the risk of exacerbations per copy of Arg16 allele in 
children and young adults with asthma on the regular long-acting β2-agonist 
salmeterol.  
4. I have shown that there is an increase in risk of exacerbations per copy of Arg16 
allele in children and young adults with asthma on frequent (once daily or more) as 
required doses of inhaled salbutamol. This effect is not observed on participants 
with asthma who are not exposed to β2-agonist on a daily basis.  
5. I have shown that the Arg16Arg variant status may be associated with worse airway 
obstruction, as measured by the FEV1/FVC ratio. 
6. I have shown that the individuals with FLG null alleles have a significantly 
increased risk of exacerbations requiring hospital admissions, courses of oral 
steroids, or experiencing school absences. 
17 
 
7. The permeability of the skin, as measured by transepidermal water loss, is around 
50% higher in children heterozygous for filaggrin gene defects compared to 
clinically unaffected children but the permeability of the intestinal barrier, as 
measured by dual sugar absorption tests, is not different. My observations provide 
for the first time, an explanation of the clinical basis for the possible increased risk 
of allergen entry in children with eczema and asthma.  
18 
 
SECTION II  
 
BACKGROUND 
 
Chapter 1  
 
Asthma Severity And Burden Of The Disease In Childhood 
 
Asthma is one of the most common chronic diseases in the world
1,2,3,4
. Genetic and 
environmental factors contribute to the development of asthma and its subsequent severity. 
Asthma is a complex syndrome with variable outcomes and this variability has made it 
difficult to appropriately monitor and control the condition. Multifaceted markers are 
necessary to adequately characterise this complex disorder
5
. There is also need to identify 
primary prevention strategies to control asthma exacerbations through interventions that 
promote adherence to asthma guidelines and reduce exposures to causes of asthma 
exacerbations
6
. 
 
Over 5million people in the UK have asthma; 1.4 million of them are children under 16 
years of age
7
. Scotland tops the ranking list by country for the prevalence of current asthma 
symptoms in the childhood and teenage years
8
. In England, an estimated 261,400 people 
were newly diagnosed with asthma in 2005; 5.7 million people had an asthma diagnosis 
and were prescribed 32.6 million asthma-related prescriptions
9
. A better understanding of 
the variability in disease and response to treatment, and interactions between the pathology 
19 
 
of disease and its clinical expression is essential to the appropriate selection of therapy and 
the maximisation of outcomes in children and young adults.  
 
Exacerbations of asthma are the commonest cause of medical admissions in childhood and 
have significant effects on quality of life
10
. Exacerbations represent periods of enhanced 
airway inflammation and remodelling
11 
and are a marker of pulmonary decline
12
. 
Potentially life-threatening asthma exacerbations are of great concern to individuals with 
asthma. They diminish the quality of life of the patients and their families
10, 13, 14
. 2.1 
million adults and 500,000 children in the UK have severe asthma symptoms including 
debilitating shortness of breath, attacks so bad that they are unable to speak, fear of death 
and emergency hospital admissions
15
. There were 40 deaths in children from asthma 
exacerbations in 2004 in the UK
16
.  In children with asthma, school absences from 
asthma
17
, use of short courses of oral steroids
18, 19
 and asthma-related hospital admissions
20
 
represent well-validated measures of asthma exacerbations. I have combined these 
measures to develop a tool for defining asthma exacerbations that has now been validated 
through previously published work
21-26
.  
 
Commonly used non-invasive measures to detect clinical deterioration include peak 
expiratory flow rate (PEFR), asthma symptom scores and increase in daily requirement of 
salbutamol as reliever medication
23
. My research underlines the importance of genotyping 
for common genotypes in children with asthma, to improve quality of life and prevent 
asthma exacerbations. An understanding of the possible relationship between gene defects, 
inheritance and asthma might generate two newer hypotheses that primary prevention 
20 
 
strategies for asthma may be more cost effective and beneficial for genotype-stratified 
population in comparison to current treatments directed at unstratified populations
27
. 
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Chapter 2  
 
The BREATHE Study 
 
Paediatric pharmacogenetic studies have the potential of improving the quality of medical 
care for children
28
. Genetic variations, such as in the genes encoding for the β2 adrenergic 
receptor (ADRB2), the gene encoding for the filaggrin protein (FLG), gene encoding for the 
matrix metalloproteinase 12 (MMP12), chitinase 3-like1 gene (CHI3L1 rs495028) have 
been shown to influence asthma phenotype, possibly through an interaction with 
pharmacological treatments
11, 21, 23, 29, 30
. Common functional polymorphic variants of the β2 
adrenergic receptor gene are known to affect the response to asthma medication
31
.   
 
Previous studies have shown that prescribing asthma medications in primary and secondary 
care in the UK are not always consistent with guideline recommendations
32, 33
.  Off-label 
prescribing for children with asthma in UK primary care is associated with worse asthma 
control
34
. In addition, the genotypic variations that can affect medication use are not 
considered in these guidelines.  
 
A database of children and young adults with physician diagnosed asthma was developed in 
Tayside and Dumfries. The database contains information on patient genotype, 
environmental factors contributing to asthma, and clinical asthma severity as defined by 
asthma medication use and frequency of asthma exacerbations
21-25
. The aim was to study 
the association between genotypic variation and clinical asthma phenotype to create a large 
22 
 
population-based database of this information. It was also anticipated that the database will 
be studied aiming to explore therapeutic response to asthma medication; and relating 
clinical effect (including drug response) to challenge test and genotyping results in the 
longer term. I continued recruitment to the BREATHE study during my period of research. 
Now the study has also been extended to Sussex to explore the variations in the clinical 
phenotype and genotype characteristics of asthma in a wider population across the UK.   
23 
 
Chapter 3 
 
Pharmacological Management Of Childhood Asthma  
 
The principles underlying therapy of asthma have remained unchanged over the past 
several decades. The aims of pharmacological management are to control symptoms including 
nocturnal symptoms and exercise-induced asthma; prevent exacerbations; achieve best possible 
pulmonary function; and minimise side effects. Bronchodilator drugs like short-acting β2 
adrenergic receptor agonists are used as reliever to reverse the bronchospasm of an asthma 
attack. Anti-inflammatory drugs like gluco-cortocoids are used to control bronchial 
inflammation in an effort to reduce the severity and frequency of asthma attacks. Patients 
with acute exacerbations of asthma are often managed by short courses of oral steroids. In 
patients who remain symptomatic despite inhaled steroid therapy, long-acting β2 adrenergic 
receptor agonists may be added as controller to the steroid regimen with good success. 
Agents like leukotriene-receptor antagonists, are directed at specific mechanisms 
underlying the initiation or progression of asthma and are also used as controller 
medication for asthma.   
 
 The British Thoracic Society (BTS) guidelines for asthma management  
Asthma in children is managed in the stepwise approach according to the British Thoracic 
Society (BTS) guidelines
18, 35
 in the UK. Initial pharmacologic treatment of childhood 
24 
 
asthma consists of ‗reliever‘ medication (short-acting β2-agonists) according to need (step 1, 
BTS guidelines) 
18. The regular ‗controller‘ therapy starts with the daily use of inhaled 
steroids (BTS step 2). When asthma control on BTS step 2 is inadequate, inhaled long-
acting 2 -agonists, e.g. salmeterol is added (BTS step 3)
18
. However, if control is still 
inadequate and there is no response to long-acting 2 –agonists, leukotriene receptor 
antagonists, e.g. montelukast or slow-release theophylline are added (BTS step 3)
18
. For 
persistent poor control, the steroid dose is increased to 800μg/day (BTS step 4)18. Finally 
for children requiring frequent short courses of oral steroids despite highest dose of inhaled 
steroids and add-on therapy, regular oral steroids are commenced (BTS step 5)
18
. Common 
measures of asthma control include the occurrence of day-to-day asthma symptoms, 
‗breakthrough‘ asthma attacks, the need for ‗reliever‘ treatment with short-acting 2 
agonists, and quality-of-life
18
.  
 
For the purpose of my studies, the asthma prescribing level was modified for physician-led 
management of asthma, as follows: step 0 – no use of inhaled salbutamol on demand within 
the past month; step 1 - inhaled short-acting 2 -agonists eg. salbutamol on demand; step 2 - 
regular inhaled steroids plus inhaled salbutamol on demand; step 3 - regular inhaled long-
acting 2 -agonists eg. salmeterol plus inhaled steroids with inhaled salbutamol on demand; 
step 4 - regular inhaled salmeterol plus inhaled steroids plus oral montelukast and/or other 
add-on medications with inhaled salbutamol on demand. 
 
25 
 
 β2 adrenergic receptor agonists 
The drugs that are most effective in relaxing the airway smooth muscle and reversing 
bronchoconstriction are the β2 adrenergic receptor agonists. They are the preferred 
treatment for rapid symptomatic shortness of breath associated with bronchoconstriction in 
patients with asthma
36, 37
. Long acting β2 agonists like salmeterol, act by directly relaxing 
airway smooth muscles and consequently causing bronchodilation. Although human 
bronchial smooth muscle receives little or no sympathetic innervation, it nevertheless 
contains large numbers of β2 adrenergic receptors. Stimulation of these receptors activates 
the Gs adenylyl cyclase- cyclic AMP pathway with a consequent reduction in smooth 
muscle tone
38
. β2 adrenergic receptor agonists also increase the conductance of large Ca
2+
 
sensitive K
+
 channels in airway smooth muscles, leading to membrane hyperpolarisation 
and relaxation. This occurs at least partly by mechanisms independent of adenylyl cyclase 
activity and cyclic AMP production and may involve the regulation of capacitative Ca
2+
 
entry by small G proteins
38-41
. 
 
Long-term treatment with a receptor agonist often leads to receptor desensitization and a 
diminution of effect. The rate and degree of β2 adrenergic receptor desensitization depend 
on the cell type. The β2 receptors on human bronchial smooth muscle are relatively resistant 
to desensitisation, whereas receptors on mast cells and lymphocytes are desensitized rapidly 
following agonist exposure
42, 43
. This may help to explain why there is little evidence that 
these drugs are effective in inhibiting airway inflammation associated with asthma. 
26 
 
However, adding a long acting β2 agonist to the inhaled corticosteroid regimen is often 
more effective in long-term control of asthma
43, 44
.  
 
 Inhaled corticosteroids 
Inhaled corticosteroids are effective in controlling airway inflammation and are considered 
the preferred therapy for persistent asthma of all ages and disease severity
45
.  Treatment 
with inhaled corticosteroids improves the control of the disease by decreasing inflammation 
in the bronchial epithelium and in the airways, decreasing airway hyper-reactivity and 
improving asthma symptoms and decreasing the frequency and severity of asthma 
exacerbations
46
. The anti-inflammatory effects of glucocorticoids in asthma include 
modulation of cytokine and chemokine production, inhibition of eicosanoid synthesis, 
marked inhibition of accumulation of basophils, eosinophils and other leukocytes in lung 
tissue, and decreased vascular permeability
46
. The profound and generalised anti-
inflammatory actions of this class of drugs explain why they are currently the most 
effective drugs in treatment and control of asthma.    
 
 Leukotriene receptor inhibitor 
Leukotriene modifying drugs act either as competitive antagonist of leukotriene receptors 
or by inhibiting the synthesis of leukotrienes. Cysteinyl leukotrienes (Cys-LT) are potent 
constrictors of bronchial smooth muscle. On a molar basis, leukotriene D4 is nearly a 1000 
times more potent as a bronchoconstrictor than histamine
47
. The cys-LT1 receptor is 
27 
 
responsible for the bronchoconstrictor effect of leukotrienes
48, 49
. Montelukast acts as 
selective high-affinity competitive antagonist to the cys-LT1 receptor
50, 51
. The effects of 
cys-LTs that are relevant to asthma are not limited to bronchial smooth muscle contraction. 
Cys-LTs can also increase micro vascular leakage, increase mucus production, and enhance 
eosinophil and basophil influx into the airways
52
. Therefore, inhibition of these non-smooth 
muscle effects of leukotrienes may also contribute to the therapeutic effects of montelukast. 
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Chapter 4  
 
The Underlying Genetics Of Asthma  
 
Asthma is a complex disorder resulting from interactions between multiple genes and 
environmental factors. However, the tools available to identify relatively modest effect 
sizes with contributions from multiple sources have been limited. The first study to 
successfully link a genomic locus (11q13) to atopic disease was not reported until 1989
53
. 
Since then, several candidate gene studies have been published so far. Unfortunately, 
results from many of these studies have not been replicated, even when apparently similar 
patient populations with similar selection criteria are used in subsequent analyses. The 
recent application of genome-wide association (GWA) studies to the analysis of allergy and 
asthma genetics have aided in combining the previously identified associations, and the 
biologic role and functional effects of variation of these candidate genes
54
.  
 
Studies of asthma genetics have raised new interest in the body‘s first line of immune 
defence, the epithelial barrier, in the pathogenesis of asthma. It is suggested that loss-of-
function filaggrin gene variants are associated with asthma susceptibility and severity
22, 23
. 
Genes involved in mediating the response to inhaled bronchodilators appear to be important 
contributors to asthma severity. Variations in the ADRB2 modulate the response to inhaled 
β agonist55, 56. The gene encoding the β2 adrenergic receptor is an intronless gene that has 
been localised to q3 1q32 on chromosome 5
57, 58, 59
. This locus is close to the locus called 
29 
 
"5q cluster" in which the genes for IL-3, IL-4, IL-5, and granulocyte-macrophage colony 
stimulating factor (GM-CSF) are located
57, 58, 59
. 
 
Recent application of the GWA study design to asthma has produced much more robust 
results and is able to do so in a hypothesis-independent manner. Additional research is 
needed to identify additional causal genetic variants, better understand and gene–
environment interactions, and explore the role of epigenetic phenomena in asthma 
susceptibility and severity in order to translate the findings to the clinical arena. 
 
I have chosen two exemplar genes for the purpose of my work presented in the thesis. 
These genes were chosen on the basis of their significant functional roles in the context of 
the clinical outcomes which are most relevant in the day-to-day clinical practice, i.e. asthma 
exacerbations and effects on drug efficacy. The FLG null mutations could affect allergen 
entry and be important for susceptibility or early sensitization and thereby increasing the 
risk of asthma attacks. The ADRB2 gene variations which affects drug efficacy and could 
affect asthma control including exacerbations. I have chosen these two genetic variations to 
explore their effects particularly on asthma exacerbations as this is common for both these 
genes.    
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Chapter 5  
 
β2 Adrenergic Receptor Gene Variations  And Asthma 
 
Retrospective genotype- stratified analyses suggest that polymorphic variations at the 16
th
 
amino acid residue of the 2 adrenergic receptor is associated with adverse effects of 2- 
agonist use in patients with asthma
60, 61
. Previous research has shown that there is an 
increased hazard for asthma exacerbations in children for the homozygous arginine-16 
genotype (Arg16Arg) of the ADRB2, especially those on regular salmeterol
21
. It was found 
that, in the children receiving salmeterol, there was a 9 fold greater risk of school absences 
due to asthma in the Arg/Arg group in comparison to the Gly16 carriers
21
. In the cohort not 
receiving salmeterol, there was no evidence of any genotype-dependent increase in school 
absences due to asthma.  The Arg16Arg children on salmeterol had a significantly 
increased risk of extended school absence of over 1week from asthma
21
.  
 
The Salmeterol Multicenter Asthma Research Trial (SMART) was conducted in United 
States during 1996- 2003 to compare respiratory- related and asthma- related outcomes in 
subjects receiving usual asthma pharmacotherapy alone or usual pharmacotherapy plus 
salmeterol
62, 63
. In the SMART study there were small but statistically significant increases 
in respiratory and asthma- related deaths and combined asthma-related death or life- 
threatening experiences in the total population in patients receiving salmeterol compared 
with placebo. It was also noted that the imbalance largely occurred in the African- 
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American subpopulation
62
. Whether this is due to factors including but not limited to a 
physiologic treatment effect, genetic factors, or patient level behaviours leading to poor 
outcome, remains unknown. However, it is hypothesized that a genetic variation in the 2- 
adrenergic receptor may influence the response to 2- agonist therapy, and the frequency of 
genetic variations in the 2- adrenergic receptor gene are higher in subgroups such as 
African Americans compared with the overall population
64
.  Analyses of previously 
published clinical trials on the long-term use of short acting 2 agonist (salbutamol) have 
also showed that this hypothesis is correct for individuals homozygous for arginine 
(Arg/Arg genotype) at the 16
th
 amino acid position of the β adrenergic receptor65. 
  
Phosphorylation of the receptor by β2-adrenergic receptor kinase or other closely related G 
protein-coupled receptor kinases is the principal mechanism of homologous desensitization 
of the β2-adrenergic receptor. Phosphorylation by protein kinase A and G protein-coupled 
receptor kinases desensitize β2-adrenergic receptor signalling, and these mechanisms may 
be involved in cell and organ homeostasis and tolerance to agonists
66
. Significant cell-type 
variation in expression of β2-adrenergic receptor kinase can be directly related to the extent 
of short-term agonist-promoted desensitization of the β2-adrenergic receptor
67
.   
The ‗on demand‘ use of inhaled short-acting β2-agonists during asthma exacerbations is 
recommended by national guidelines and represents the cornerstone of asthma management 
worldwide
18, 68-70
. Previous research has shown that there is an increased risk for 
exacerbations in asthmatic children and young adults homozygous for the Arg16 variant of 
the Arg16Gly ADRΒ2 genotypes 
21
. In addition, the risk of possessing the Arg16 variation 
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was significant in asthmatics on regular inhaled long-acting β2-agonists, with a gene/dosage 
effect for the Arg16 variant
21
. 
 
Irrespective of regular salmeterol use, asthmatics are routinely advised inhaled short-acting 
β2-agonists on demand (e.g., before exercise, after allergen or cold air exposure or when 
they are developing exacerbations) 
18, 69, 70
. This is a treatment strategy which is globally 
adopted in current guidelines and regularly scheduled use of salbutamol is no longer 
recommended
18, 35
. Several studies on older adults have suggested that homozygous Arg16 
status is associated with reduced peak flows and increased exacerbations in asthmatics 
treated with regularly scheduled but not on demand short-acting β2-agonists
63-65, 71
. 
However, the role of the Arg16 allele on exacerbations in steroid treated asthmatic children 
using ‗on demand‘ short-acting β2-agonists per se has not been assessed. 
 
Further to the previous study
21
, we have now doubled the size of the BREATHE cohort, 
aiming to address a number of additional questions, and have examined the association of 
the Arg16 variant with exacerbations upon exposure to both long and short acting β2-
agonists.  
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Chapter 6 
 
Filaggrin Null Mutations In Childhood Asthma 
 
Filaggrin is a highly abundant epidermal structural protein facilitating epidermal 
differentiation and skin barrier formation
72
. The FLG gene, located on human chromosome 
1q21.3, encodes the giant (>400 KDa) polyprotein profilaggrin, which consists of 10-12 
tandemly repeated filaggrin subunits
73
. Profilaggrin accumulates in dense granules within 
the keratinocytes of the stratum granulosum, the last living cell layers of the epidermis. 
Upon terminal differentiation of these cells to form the stratum corneum, the chemically 
modified, dead layers of the outermost epidermis, within which the skin barrier function 
resides, the inert profilaggrin molecule is proteolytically processed into multiple copies of 
active filaggrin. The liberated filaggrin aggregates the keratin cytoskeleton leading to cell 
compaction and squame formation. Enzymatic cross-linking of the protein and lipid 
components of the newly formed squames leads to formation of a chemically impermeable 
barrier whose function is to retain water and resist entry of antigens, allergens and irritants 
from the environment
72
.  Disruption of barrier formation due to a reduction or complete 
absence of epidermal filaggrin expression has been postulated to lead to chronic 
transcutaneous antigen/ allergen/ irritant transfer, which via a TH2-mediated immune 
response, leads to atopic eczema and secondary allergic reactions, importantly including 
atopic asthma
22, 74
. 
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Previous work has shown that polymorphic variation of the filaggrin gene is involved in 
regulating the overall burden of asthma
22, 23
. This occurs through an increase in asthma 
susceptibility
22
 and also an increase in medication requirements
23
 in children with 
established asthma. Weakening of physical barrier of skin in FLG deficient individuals may 
potentiate the effect of relevant environmental exposures. There is also evidence of 
significant interaction between the filaggrin loss-of-function mutations and cat exposure at 
birth on the development of early-life eczema
75
.  
 
Two independent mutations in the gene encoding filaggrin (FLG; R501X and 2282del4), 
carried by about 9% of people of European origin, result in the loss of processed functional 
filaggrin in the epidermis
22, 76
. These genetic mutations, previously proven to impair the 
formation of stratum corneum
76
, strongly predispose to childhood eczema in several white 
European populations, where these mutations are prevalent
22, 77-82
, including Scottish, 
English, Irish, Danish and German populations. Analogous mutations leading to loss of 
function have been recently reported to be significantly associated with atopic dermatitis 
and ichthyosis vulgaris in the Japanese population
83
 and may even predict more severe and 
persistent forms of atopy
78
. This gene may contribute to atopic disease burden to varying 
degrees worldwide. Recently, the genetic architecture of filaggrin-related atopy has been 
shown to consist of a combination of a small number of prevalent null mutations as well as 
several rare or family-specific mutations
73
, as recently reviewed
84
. 
 
The combined genotype of the two most prevalent filaggrin variants in Europeans, R501X 
and 2282del4, was the focus of the previous work from our group
22
. However, further work 
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suggested that the R501X mutation may have greater penetrance in determining higher 
serum IgE levels in patients with atopic eczema in comparison to those carrying the 
2282del4 mutation
82
. As similar penetrance differences may occur in asthma, the relative 
effects of the null mutations as well as the combined genotype, on the asthma severity 
outcomes and symptomatic control measures of the BREATHE study, require to be 
compared. The previous data had demonstrated that individuals with FLG null alleles have 
a significantly increased disease burden, both in terms of lung function, the null mutation 
carriers having greater airway obstruction, and in the intensity of medication required for 
disease control
23
. The individual contribution to the overall signal of the 2282del4 allele 
was lower than that observed for the R501X mutation. However the association of these 
mutations with the risk of asthma exacerbations has never been assessed. In asthmatic 
children, asthma-related school absences
17
, requirement of oral steroids
18, 19
 and hospital 
admissions
20
 represent well validated measures of asthma exacerbations. A combined score 
has been developed by our group, involving yes/no responses for any of the above three 
measures of exacerbations over a 6 month period of reporting, to explore asthma 
exacerbation risk from PPAR  genotype variation
24
. Here I have used this score to compare 
the relative effects of the two filaggrin mutations and the combined genotype on the risk of 
asthma exacerbations. I also explored in this study the relative penetrance of the 2 
mutations and the combined genotype on a larger asthmatic population. 
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Chapter 7 
 
Epithelial Permeability And Filaggrin 
 
The filaggrin protein present in the stratum corneum is thought to maintain skin barrier 
integrity in at least 2 ways. Firstly, it arranges the keratin filaments into structural scaffolds 
and secondly it osmotically maintains skin hydration
72, 85, 86
. It is now known that children 
with common (approximately 9% of the population) loss-of-function mutations in this 
protein are more likely to suffer from early-onset eczema, asthma and other allergies such 
as to grass pollen, cat and house dust mite
22, 75
. Interestingly, filaggrin is not expressed in 
the bronchial mucosa
87
, which has led others to suggest that asthma susceptibility in 
patients with loss-of-function FLG variants may be due to allergic sensitization that occurs 
as a result of a weakened epidermal barrier
88
. 
 
Filaggrin is essential for the cell compaction process preceding chemical cross-linking 
during the genesis of the stratum corneum. Therefore, it is a key molecule in the initiation 
and maintenance of skin barrier function
89
. The terminal degradation products of filaggrin 
may also act as a ‗‗natural moisturizing substance‘‘82. FLG mutations are an important 
predisposing factor for atopic dermatitis and secondary atopic phenotypes like asthma, 
suggests that the skin barrier defect is a primary key event leading to allergic sensitization 
and development of atopic phenotypes
90
. 
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Through literature searching I sought to identify a technique that could measure the 
differences in epidermal permeability between children carrying filaggrin gene defects and 
controls. Transepidermal water loss (TEWL) and stratum corneum hydration, which are 
measurements of skin barrier function, were reported to increase in patients with atopic 
dermatitis due to their skin barrier insufficiency
91, 92
. Significant correlations were observed 
between penetration rates of a hydrophilic dye and elevated IgE levels in patients with 
severe atopic dermatitis
93
. Skin barrier function could be evaluated by measurements of 
TEWL, stratum corneum hydration, and thickness that are useful markers of skin barrier 
function
94
. In ichthyosis vulgaris, the epidermal barrier function measured by TEWL is 
known to be associated with the severity of the disease
95
. Additionally, in patients with 
atopic dermatitis, TEWL was increased, although controversy still remains as to whether 
the defective barrier function in atopic dermatitis patients is a primary cause of atopic 
dermatitis or a secondary consequence following dermatitis
96
. 
 
Transepidermal water loss represents the outward diffusion of water through skin and its 
measurements are used to gauge skin barrier function
97
. Readings increase when the 
integrity of the stratum corneum barrier is compromised, and they correlate with 
percutaneous absorption
98
. Few studies have characterized TEWL
99
 in young children with 
atopic dermatitis, and studies in children have not compared altered epithelial permeability 
in children with filaggrin defects versus the normal population. 
 
The three possible routes of allergen entry in humans resulting in atopic diseases are the 
skin, respiratory tract and gastro-intestinal tract. A previous study has identified the 
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presence of filaggrin in the human hard palate and buccal mucosa, but not in the nasal 
(inferior turbinate) mucosa, or in the oesophagus (proximal, mid or distal) 
100
.   
In routine clinical practice it has been observed, that the removal of the food allergen from 
the patient's diet leads to a significant clinical improvement in children with atopic 
dermatitis. A possible hypothesis is that the IgE-bearing dendritic cells help in the 
circulation of allergen from the gastro-intestinal tract to the skin and activate local T cells 
to result in atopic diseases. However, simultaneous evaluation of epidermal barrier 
impairment measured using a tewameter, and the risk of allergen sensitization by 
measuring the permeability of the gastro-intestinal tract, has not yet been performed in 
children. 
  
I performed a pilot study to noninvasively explore the permeability changes in the skin and 
the intestine, in order to help identify the primary site of allergen entry in humans. 
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                                          SECTION III  
 
METHODS 
 
The BREATHE study was approved by the Tayside Committee on Medical Research and 
Ethics. Informed consent was provided by the patient and parent/ guardian as relevant, in 
compliance with all principles of the Helsinki Accord
101-103
. 
 
Chapter 1  
 
Personal Interview 
 
Clinical and genotype information were collected from 1182 children and young adults 
with physician diagnosed asthma for the BREATHE study using a simple questionnaire 
(figures 3.1.1 and 3.1.2). The dataset includes information about demographic, 
anthropometric and clinical details from 1182 individuals attending primary and secondary 
clinics in Tayside and Dumfries, Scotland, from 2004 to 2008 (age 3-22 years). The data 
was collected on 546 children previously and has now been extended to 1182 of which I 
collected data from 411 participants, working with Ms Inez Murrie.  
 
All asthma patients were recruited through 29 primary care practices and 2 secondary care 
asthma clinics. Asthma was diagnosed by the physicians according to the Scottish 
Intercollegiate Guidelines Network/British Thoracic Society Diagnostic Guidelines
18
.  
40 
 
 
The clinical patient data for the study was collected through the paediatric wards and 
asthma clinics of Ninewells Hospital and Perth Royal Infirmary, Tayside, or through pre-
arranged visits to primary care. An initial search was carried out to identify patients and the 
parents and patients were contacted as appropriate. History and baseline clinical data were 
collected. The diagnosis of asthma, and allergy test results were obtained from the medical 
records, while the rest of the data were obtained from parental recall. Saliva samples were 
collected for genotyping and archiving. All data were anonymised. Each salivary sample 
was coded with a unique number, not the child‘s name or hospital identification number. 
These were stored completely separately. No computer file contains both names and study 
numbers, and all study information is identified by the study numbers. 
 
The patients were seen in the asthma clinic setting, where a detailed personal and family 
history was obtained including detailed quantified information on school absences, courses 
of oral steroids and hospital admissions over the previous 6 months. In addition, parents 
were asked, ‗‗has your child ever had eczema or an itchy rash?‘‘ For the assessment of 
seasonal rhinitis, the parents were asked, ―does your child have hayfever or does he/she 
sneezes more in a particular time of the year?‖ ―Does your child have runny nose most of 
the time of the year?‖ was asked to assess for perennial rhinitis. The asthma prescribing 
level was determined as the modified BTS guidelines for physician-led management of 
asthma, as follows: step 0 – no use of inhaled salbutamol on demand within the past month; 
step 1 - inhaled short-acting 2 -agonists eg. salbutamol on demand; step 2 - regular inhaled 
41 
 
steroids plus inhaled salbutamol on demand; step 3 - regular inhaled long-acting 2 -
agonists eg. salmeterol plus inhaled steroids with inhaled salbutamol on demand; step 4 - 
regular inhaled salmeterol plus inhaled steroids plus oral montelukast and/or other add-on 
medications with inhaled salbutamol on demand. From this data a global index of asthma 
severity was derived through construction of a composite variable, as reported previously
24
. 
Steps 0 and 1 were considered as mild asthma while steps 2, 3 and 4 were included in the 
moderate to severe group. The changes in medication within the previous 6 months were 
recorded as well. 
 
Family history for asthma, eczema and allergic rhinitis were explored and expressed as 
present or absent. Asthma related school absences
17
 (days off work/university for young 
adults) use of short courses of oral steroids
18, 19
 and admission to the hospital
20
 due to 
severity of asthma (minimum once over the previous 6 months) were grouped as present or 
absent. The total asthma exacerbation response was defined as the presence or absence of 
any of these measures during this period of time. This was again grouped as present or 
absent to create an asthma exacerbation yes/no response that has been validated as a 
measure of asthma severity through several publications
21, 23-26, 104, 105
. Although the 
individual measures for asthma exacerbations have been used for assessment of 
exacerbation of asthma in children and young adults
17-20
, the composite exacerbations 
scoring system has not yet been externally validated. 
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Figure 3.1.1: The BREATHE study questionnaire page 1 
 
                    BREATHE STUDY 
          (Children’s Genotype Project) 
   
 
 
Name__________________________________ 
Address________________________________ 
_______________________________________ 
_______________________________________ 
Name of Parent___________________________ 
Mother’s DOB___________________________ 
GP_____________________________________ 
Height (cms)_____________________________ 
Date & Source___________________________ 
DOB/CHI____/___/____________ 
Occupation___________________ 
Telephone Number_____________ 
Mobile Number________________ 
Email________________________ 
Father’s DOB__________________ 
Health Centre__________________ 
Weight (Kgs)__________________ 
Date Data Entered______________ 
History 
Does the child have: Eczema      Perennial rhinitis       Seasonal rhinitis  
Does anyone else in the family have: 
 Mother Father Siblings Other None 
Asthma      
Eczema      
Allergic rhinitis      
 
Does the child have any allergies? 
Agent Reaction 
  
  
  
 
Known triggers for asthma? 
  
  
 
Does the child/ young adult smoke? Yes No 
If yes, how many per day? ________________ 
 
Is the child exposed to smoking? 
 
At home           With Relatives           With Childminder                 Other                
Not exposed  
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Figure 3.1.2: The BREATHE Study questionnaire page 2 
 
Is the child exposed to animals?      Cat       Dog         Horse            Bird   
 Other (Specify)_______________  Not exposed  
 
Has the child ever had an allergy test? Yes  (SPT /RAST )    No  
Results:___________________________________________________ 
__________________________________________________________ 
 
Current Medication 
Drug Device Dose per puff Frequency 
    
    
    
    
    
 
Inhaler technique                   Good     Poor      Not applicable  
 
Bronchodilator use in the last 6 months:  None  Occasional  Daily  Excessive  
Comments_____________________________________________________ 
 
Courses of oral steroids in the last 6 months__________________________ 
 
Number of hospital admissions in the last 6 months_____________________ 
 
Absence from school/ nursery/ college/ work?  
None         1-2 days           Up to 1 week            > 1 week           
 
Lung Function 
 
 PEFR FEV1 FVC FEV1/FVC 
Predicted     
Actual     
% Predicted     
Reversibility     
Actual (post β2)     
% Change     
 
Other Information______________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
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Chapter 2  
 
Pulmonary Function Tests  
 
Pulmonary function tests were performed using the Microlab ML3500 MK8 portable  
Spirometer
106, 107
 (Micromed, Rochester, United Kingdom). It uses a stable form of  
transducer known as a digital volume transducer. This measures the expired air 
directly at body temperature and pressures with saturated water vapour and avoids 
the inaccuracies of temperature corrections. The transducer is insensitive to the 
effects of condensation and temperature. It was used to measure the forced spirometry 
to measure forced vital capacity (FVC), forced expiratory volume in 1 second 
(FEV1), forced expiratory flow 25% to 75% (FEF 25-75) and peak expiratory flow 
(PEF). The ratio of forced expiratory volume in 1 second (FEV1) to forced vital  
capacity (FVC) constitutes an established index of airway obstruction
108
. This ratio  
was used as the primary measure of airway obstruction for the study.  All the  
values were corrected for age, sex and height of the participant and the  
percentage predicted values were taken into account. The calibration of the  
machine was routinely done by a 3litre syringe connected to the transducer. A  
calibration error of 3% was considered acceptable as per the American Thoracic 
Society/ European Respiratory Society recommendations
106
. 
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The subjects were instructed to take a deep breath in and exhale as forcefully and long as 
possible into the mouthpiece attached to the transducer so as to empty their lungs. At least 3 
measurements were taken to calculate a mean for each individual. The results were printed 
on thermo stable printer paper. 
 
The pulmonary function data were collected at a single visit. A minimum of 3 results within 
10% of each other was recorded, and the result with the highest FEV1 was analyzed. The 
participants were not suffering from asthma exacerbations or other acute illnesses at the 
time of the measurement of pulmonary function. The lung function test results were 
expressed as a percentage of that predicted using the data of Rosenthal et al
107
. 
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Chapter 3  
 
Saliva Collection For DNA and Genotyping 
All DNA samples were collected from the saliva with informed consent
101-103
. The saliva 
was collected by two methods.  
 
 Mouthwash method 
 
It was ensured that the participant has not eaten or cleaned their teeth immediately before 
taking the sample. The participant was encouraged to take 4-5mls of clean tap water into 
his/ her mouth and swirl around the mouth for approximately 20-30 seconds. The sample 
was then spit back into a universal container. The container was sealed correctly and 
labelled with the study identification number, not the patient‘s name, and that the correct 
patient details were associated with the identification number. This technique was very easy 
to perform, did not require any special expertise and was child-friendly.  
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 Saliva collection by Oragene® DNA collection kit 
 
Oragene® DNA is a non-invasive DNA collection kit that is used by untrained study 
participants including children and elderly (http://www.dnagenotek.com). The median 
DNA yield from 2ml Oragene® saliva samples is about 110 microgram. This kit was used 
for DNA yield, preservation and purification. It has low bacterial content and is equivalent 
to DNA from blood for downstream applications. The preservation and storage of DNA 
samples was of immense importance for this study. The DNA from saliva is stable in this 
kit for up to 5 years in room temperature. The stability is achieved with proprietary reagents 
that inactivate bacteria and nucleases in saliva and minimize chemical hydrolysis of DNA.  
 
Figure3.3.1: Oragene® DNA collection kit 
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 Children over 5 years of age were encouraged to have a drink of water prior to providing 
the sample. After a few minutes they were requested to spit in the container directly, up to 
the mark. The drink prior to the procedure would have enhanced the production of saliva. 
Then the container was tightly closed so that the solvent came to contact with the sample. 
This allowed preservation of the sample in room temperature. 
 
Figure 3.3.2: Method of collection of saliva in the Oragene® DNA collection kit in 
children older than 5 years of age  
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Figure 3.3.3: Collection of saliva by the Oragene®
®
 DNA 
collection kit in a child under 5years of age. 
 
 
In younger children, a saliva sponge was placed in the child‘s 
mouth in the space between the gums and the inner cheek. The 
saliva sponge was gently moved around the upper and lower 
cheek pouches on both sides of the mouth to soak up as much as 
saliva as possible. The sponge was left in the child‘s mouth for 
about 60seconds.  
 
Once collected, the sponge was cut into the blue base of the 
Oragene® kit as shown in figure. The sponge was then placed 
firmly against the bottom of the kit between the tooth and the kit 
wall. This action ensured that the sponge tip remains in the 
container during the cutting action. Using the scissors provided, 
the narrow part of the handle was cut just above the sponge. 
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Figure 3.3.4: Method of cutting the saliva sponge and placing in the kit 
 
         
 
 
For the collection of up to five saliva sponges, these steps were followed at 5 minute 
intervals. The kit was then carefully capped and tightened firmly. The Oragene® liquid 
released from the cap preserved the DNA collected by the sponges. The samples were then 
sent in batches to the Biomedical Research Institute, University of Dundee, for genotyping.  
 
51 
 
 
Genotyping  
 
The genotyping was done at the Biomedical Research Institute, University of Dundee. I 
have observed the methods of genotyping being performed by Dr Roger Tavendale in 
Professor Colin Palmer‘s laboratory.   
 
DNA was prepared using the Qiagen Dneasy 96 kit, and genotypes were determined using 
Taqman-based allelic discrimination assays on an ABI 7700 sequence detection system
114
. 
The DNA was archived for future research. 
 
 FLG R501X and 2282del4 
 
All primers and probe sequences have been shown in previous publication
22
. Mutation 
R501X creates a new NlaIII restriction enzyme site, and 2282del4 creates a new DraIII site, 
which were used to screen short, highly specific PCR fragments for these variants, as 
described previously
22
. Genotyping for R501X was also performed using a TaqMan-based 
allelic discrimination assay (Applied Biosystems). Standard procedures were used based on 
Applied Biosystems reagents and 10-µl reaction volumes. Allelic discrimination was 
assessed using an Applied Biosystems 7700 sequence detection system. Mutation 2282del4 
was also genotyped by sizing a fluorescently labelled PCR fragment on an Applied 
Biosystems 3100 or 3730 DNA sequencer. Ten-micro litre PCR reactions were carried out 
using primers DEL4.F2 and DEL4.R1 in AmpliTaq Gold buffer containing 1.5 mM MgCl2 
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(Applied Biosystems), 10 nmol of each dNTP and 1 unit AmpliTaq Gold DNA polymerase. 
Reactions were amplified as follows: 94ºC (12 min), one cycle; 94 ºC (15 s), 58 ºC (30 s) 
and 72 ºC (45 s), 30 cycles; and 72 ºC (5min), one cycle. Fragments were diluted 1:60 and 
sized against ROX-500 size markers according to the manufacturer‘s recommended 
protocol (Applied Biosystems). The wild-type allele was 199 bp, and the 2282del4 allele 
was 195 bp. 
 
AA refers to the wild- type FLG genotype for R501X and 2282del4 mutations, Aa refers to 
heterozygous genotype for either R501X or 2282del4, and aa refers to homozygous R501X 
or 2282del4 genotype or compound heterozygous genotype. The homozygous, 
heterozygous and compound heterozygous genotypes were considered together as Aa/aa.  
 
 Gly16Arg and Glu27Gln 
 
DNA was prepared using the Qiagen Dneasy 96 kit, and genotypes were determined using 
Taqman based allelic discrimination assays on an ABI 7700 sequence detection system
114
. 
For the Gly16Arg variant, the following probes and primers were used:  
forward primer: GAACGGCAGCGCCTTCT;  
reverse primer: GCACATTGCCAAACACGATG; 
Arg16 probe: Cal Orange or VIC-CACCCAATAGAAGCCATGCGCCGGACCACGAC-
BHQ; Gly16 probe: FAM-CACCCAATGGAAGCCATGCGCCGGACCACGAC-BHQ. 
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For the Glu27Gln variant the forward primer was identical to the forward primer for the 
Gly16Arg variant. 
reverse primer: TGAGAGACATGACGATGCCC.  
Gln27 probe: Cal Orange-or VIC-
CCATGCGCCGGACCACGACGTCACGCAGCAAAGGGACGA-BHQ; 
Glu27 probe: FAM-CCATGCGCCGGACCACGACGTCACGCAGGAAAGGGACGA-
BHQ.  
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Chapter 4 
 
Measurement of Transepidermal Water Loss 
  
Skin hydration and integrity, as measured by transepidermal water loss, are important 
parameters for objectively quantifying atopic dermatitis in children. Transepidermal water 
loss was measured by a non-invasive technique using Tewameter (CK electronic GmbH)
 
109-111 
website: www.courage-khazaka.de). The measurement of the water evaporation is 
based on the diffusion principle in an open chamber dm/dt = D X A dp/dx; where A= 
surface in meter
2
, m=water transported (in gram), t= time (hours), D= diffusion constant, 
p= vapour pressure of the atmosphere (mm Hg), x= distance from skin surface to the point 
of measurement (meter) (www.courage-khazaka.de). The density gradient is measured 
indirectly by the two pairs of sensors (temperature and relative humidity) inside the hollow 
cylinder and is analysed by a microprocessor. The small size of the probe head minimizes 
the influence of air turbulences inside the probe. Also the low weight of the probe has no 
influence on the skin surface structure and allows easy handling. All the calibration data are 
inside the probe. Therefore the probe is self-contained.  
 
The measuring principle is based on the open chamber measurement. With this method, 
continuous measurements are possible without any influence on the skin surface. For stable 
measurements the Probe Heater PR100 keeps the probe head to a certain temperature of 28-
32
o
C (corresponding the skin temperature). 
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I placed the probe on the participants forearm, midway between the wrist and elbow. The 
recording of measurement was represented graphically on the computer. Measurements 
were allowed to stabilise for around 5 minutes before recordings were made for a 2 minute 
period, and the mean rate of water loss calculated for the 2 minute time period. 
Measurements were made at least 3 times in total for each participant and an overall mean 
transepidermal water loss calculated. The skin permeability of one child was higher 
compared to the others. To maintain consistency in the operating procedure, the 
measurement was not repeated, however, the participant was excluded from the final 
analysis. 
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Figure 3.4.1: Tewameter and the probe 
 
 
 
Figure: 3.4.2: Graphical representation of the transepidermal water loss measurement 
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Chapter 5 
 
Dual Sugar Test 
 
Dual sugar absorption test is a non-invasive test of intestinal permeability and has been 
used to assess the permeability of the small bowel mucosa, in a variety of intestinal 
diseases. In these tests, the permeability to nonmetabolizable mono- and disaccharides like 
mannitol/ lactulose or rhamnose/cellobiose is compared and expressed as the ratio of the 
concentrations of these saccharides in a timed urine sample
112
. Lactulose/mannitol 
excretion ratios have been proposed as a useful, non-invasive test for screening and 
monitoring celiac disease
112
. Following overnight fast, the participants drank a solution 
containing lactulose, a non-metabolised, high molecular weight sugar (0.1g/kg body 
weight) and mannitol, a readily absorbed, low molecular weight sugar (0.1g/kg body 
weight) (volume drunk= 1ml/kg of body weight). The participants did not have any food or 
drink for two further hours. They were then given 500 mls of water to drink. All urine 
produced during the 5 hour period following ingestion of the sugar solution was collected 
in a container with 10mg of gentamicin, to prevent bacterial consumption of any excreted 
sugar. The total volume of urine was measured and a small aliquot (3-5 mls) further sample 
was frozen. 
 
The content of the sugars lactulose and mannitol were measured using high pressure anion 
exchange chromatography with pulsed amperometric detection
112-113
. This assay was 
performed by Dr Simon Fleming (Clinical Biochemistry, Royal Cornwall Hospital).  
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Chapter 6  
 
Statistical Analyses 
 
I have used SPSS for Windows versions 14-16 (SPSS Inc, Chicago, Ill) for all the statistical 
analyses. 
 
 β2 adrenoceptor genotype variation and asthma exacerbations  
 
The dataset used for this analysis includes information about demographic, anthropometric 
and clinical details from 1182 individuals attending 29 primary care practices and 2 
secondary care asthma clinics in Tayside, Scotland, from 2004- 2008 (age 3-22 years). A 
detailed history was obtained including information on school absences, usage of oral 
steroids and hospital admissions over the previous 6 months. For simplicity and greater 
accuracy through recall, only yes/ no responses for any of the three options were used for 
analysis. 
 
Binary logistic regression was used to calculate odds ratios and P values for asthma 
exacerbations. To calculate the odds ratios (ORs) for comparison of risk, measures for 
asthma exacerbations were grouped according to severity. School absences, intake of oral 
steroids and admission to the hospital due to severity of asthma were grouped as present 
(minimum once over the previous 6 months) or absent. The total asthma exacerbation 
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response was calculated as any of these measures during the same period of time. This was 
again grouped as present or absent. 
 
In order to explore the associations, I used a co-dominant model 0=Gly16Gly, 
1=Gly/Arg16, 2=Arg16Arg, as has been previously examined
21
. Age, gender, and exposure 
to tobacco smoke were included in all models as covariates after step-wise removal 
procedures (covariates with p<0.2 retained).  Seasonality, another potential covariate, did 
not contribute significantly to the model (p >0.4) and was not associated with genotype in 
any subgroup tested and hence was excluded from the final analysis. 
 
I tested the effect of the Arg16 allele on asthma exacerbations in relation to inhaled β2-
agonist use from a number of different perspectives. Firstly, I tested the overall effect of the 
Arg16 allele on the individual measures of asthma exacerbations and on the overall risk of 
exacerbations. Secondly, I also tested the association of the genotype of ADRB2 and 
exacerbations over asthma treatment steps 0-4 and in participants using regular salmeterol 
versus those not using regular salmeterol, in order to identify any treatment steps where the 
effect could be more prominent than others. Finally, I tested the hypothesis that there is an 
interaction between genotype and the daily use of any inhaled β2-agonist (as required 
salbutamol and/or regular salmeterol) on the risk of asthma exacerbations. I also tested the 
association of Glu27Gln genotype with exacerbations conditioned on Arg16Gly 
polymorphic variation. Significance was predetermined at p <0.05.  
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 FLG null mutations and asthma exacerbation study 
 
The dataset includes information about demographic, anthropometric and clinical details 
from 1135 individuals attending primary and secondary clinics in 29 primary care practices 
and 2 secondary care asthma clinics in Tayside and Dumfries, Scotland, from 2004 to 2007 
(age 3-22 years). 
 
To calculate the ORs for comparison of risk, measures for asthma exacerbations were 
grouped according to severity. School absences, intake of oral steroids and admission to the 
hospital due to severity of asthma were grouped as present (minimum once over the 
previous 6 months) or absent. The total asthma exacerbation response was calculated as any 
of these measures during the same period of time. This was again grouped as present or 
absent. Chi-square test was used to compare the effects of the mutations on total asthma 
exacerbations as well as its constituent measures. Significance was assessed at p <0.05. 
Both one-tailed and two tailed p-values are shown due to the predictable nature of the 
direction of effect of the variants of the traits under test. 
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 Epithelial permeability in FLG null mutations- A pilot project  
 
10 participants, heterozygous for the filaggrin null alleles, were recruited from the 
BREATHE study. The 14 control participants were volunteers who were not genotyped and 
did not have asthma or eczema. The median values for the skin and intestinal permeability 
tests were compared using the Mann Whitney test. A p value below 0.05 was considered 
significant. 
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                                                 SECTION IV  
 
RESULTS 
 
Chapter 1  
 
Description Of the BREATHE Cohort 
 
The population characteristics are fairly typical of young individuals with well controlled 
asthma derived from both primary and secondary care
115
 (Table4.1.1). 1182 participants 
were Caucasian and the data from other ethnic groups were not sufficient for further 
analysis. The mean age for the study children was 10.3 ±4.05 years. 58.8% of the children 
were boys and 41.2% were girls. Mean body mass index (BMI) for the study children was 
19.19± 4.32. According to the modified British Thoracic Society guidelines for treatment 
of asthma, 17.5% children were on step 1, 56% on step 2, 13.3% on step 3 and 10% were 
on step 4.  
 
Overall prevalence of asthma exacerbations over the previous 6 months was 38.2%. The 
individual measures for exacerbations were also explored. 32.1% children needed days off 
school in the previous 6 months, 21.7% required a course of oral steroid and 13.1% 
children were admitted to hospital due to exacerbation of their asthma. 
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The family history of asthma, eczema and allergic rhinitis were explored and described in 
table 4.1.2. There was positive maternal history of asthma in 24.2%, eczema in 14% and 
allergic rhinitis in 25.5%. Positive paternal history for asthma was present in 19.4%, 
eczema in 7% and allergic rhinitis in 15.6%. Siblings of these children and young adults 
suffered from asthma in 30.2%, eczema in 21.1% and allergic rhinitis in 16.3%. 
 
Table 4.1.3 describes the personal history of the participants as obtained during the 
interview. 52.6% children suffered from eczema. 21.2% suffered from perennial rhinitis 
and 23.4% suffered from seasonal rhinitis. 33.3% children were exposed to cigarette smoke 
and 62.3% were exposed to animals. Figure 4.1.1 describes the common domestic animals 
the children were exposed to.  
 
Figure 4.1.2 describes the common asthma medications used in the participants. The 
commonest medication used for control and management of asthma was beclomethasone 
dipropionate (53%). Seretide (salmeterol with fluticasone) (16%) was the second most 
commonly used drug in children with asthma for their long term treatment. Montelukast 
was used by 11% of the participants. 
 
Figure 4.1.3 describes the common allergens responsible for the atopy in the participants. It 
was noted that the common allergens responsible for atopic diseases were cat fur (20%), 
house dust mite (20%), dog hair (16%) and grass (16%). This was observed on the result of 
the skin prick test performed on the child in the past. 
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Table: 4.1.1: Demographic and clinical characteristics of participants for the     
                       BREATHE study (n=1182) 
 
 
Mean (SD) age (years) 10.34 (4.0); (<18=1137; 
≥18= 45) 
Sex (Male/Female) 703/ 479 (58.8%/41.2%) 
Mean (SD) body mass index 19.13 (4.5) 
Pulmonary function (n=915)¶ 
Mean (SD) PEFR (% of mean predicted) 87.66 (17.8) 
Mean (SD) FEV1 (% of mean predicted) 95.83 (15.5) 
Mean (SD) FVC (% of mean predicted) 92.20 (14.4) 
Mean (SD) FEV1/FVC (% of mean predicted) 102.39 (9.7) 
Modified British Thoracic Society (BTS) step of 
asthma treatment* 
0= 39(3.3%); 1= 204 
(17.3%); 2= 660 (56%);  
3= 157 (13.3%); 4= 117 
(10%) 
 
Inhaled bronchodilator use† 0= 137 (11.6%); 1= 827 
(70%); 2= 186(15.7%); 3= 
31(2.6%) 
School absences over previous 6 months  382(32.3%) 
Courses of oral steroids over previous 6 months 263 (22.3%) 
Hospital admissions over previous 6 months 157 (13.3%) 
Overall asthma exacerbations over previous 6 
months‡ 
456 (38.6%) 
 
KEY: SD: standard deviation;  PEFR: Peak expiratory flow rate; FEV1: Forced expiratory volume in 1 
second; FVC: Forced vital capacity; *Step 0 – no use of inhaled salbutamol on demand within the past month; 
Step 1 - inhaled salbutamol on demand; Step 2 - regular inhaled steroids plus inhaled salbutamol on demand; 
Step 3 - regular inhaled salmeterol plus inhaled steroids with inhaled salbutamol on demand; step 4 - regular 
inhaled salmeterol plus inhaled steroids plus oral montelukast and/or other add-on medications with inhaled 
salbutamol on demand; †Inhaled bronchodilator use: 0= none, 1= occasional (more than once a week and less 
than daily use), 2= daily (200 mcg/ day required for symptom control), 3= excessive use (use of more than 
one dose of 200 micrograms/ day for symptom control); ‡Defined as any one of the following in previous 6 
months: school absences, courses of oral steroids, or hospital admissions  
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Table: 4.1.2: Family history of asthma, eczema and allergic rhinitis in the study 
population (n=1182) 
 
 
 
 
 
 
 
 
 
 Asthma  Eczema  Allergic rhinitis  
Maternal 283 (23.9%) 161 (13.6%) 305 (25.8%) 
Paternal 231(19.5%) 85 (7.2%) 188(15.9%) 
Siblings 358 (30.3%) 249 (21.1%) 194 (16.4%) 
Other 567 (47.9%) 279 (23.6%) 207 (17.5%) 
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Table: 4.1.3: Personal history of the participants of the BREATHE study (n=1182) 
 
 
 
 
 
 
 
 
Eczema (%) 
 
607 (51.4%) 
Perennial rhinitis (%) 255 (21.6%) 
Seasonal rhinitis (%) 279 (23.45) 
Smoking (%) 24/ 1158 (2.0%) 
Exposure to smoke (%) 394/ 750 (33.3%) 
Exposure to animals (%) 736/ 446 (62.3%) 
Triggers for asthma exacerbations as reported by parents 
 
Cold 386 (32.7%) 
Exercise 445 (37.6%) 
Viral illness 626 (53.0%) 
Others 
 
402 (34.0%) 
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Figure 4.1.1: Pie chart illustrating the exposure to animals  
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Figure 4.1.2: Medications prescribed for asthma control in Tayside and Dumfries 
(n=1182) 
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Figure 4.1.3: Common allergens positive on skin prick test (n=136) 
 
 
 
 
 
 
KEY: 136 out  of 1182 participants had skin prick test done as part of clinic work-up 
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Chapter 2  
 
Effects Of β2-adrenergic Receptor Gene Variations in Asthma Exacerbations 
 
The population characteristics are described in details in table 4.2.1. Table 4.2.2 describes 
the medication use and episodes of exacerbations of asthma in the study participants. The 
prevalence of the Arg16Arg genotype was 15.3%, Arg16Gly 43.8% and Gly16Gly 40.8% 
(table 4.2.1) in children and young people with asthma within Tayside (Minor allele 
frequency= 0.37) (table 4.2.3). The minor allele frequency (MAF) was similar to that 
observed for the US and UK populations
21, 65, 116
 (MAF 0.35 and 0.36 respectively)
 64,117
.   
 
An increased risk per copy of the Arg16 allele, of requirement of short courses of oral 
steroids due to asthma exacerbations was observed (OR: 1.27; 95% CI=1.04-1.56 (p= 
0.02)) (table 4.2.4). Table 4.2.5 describes the overall effect of the Arg16Gly genotype in the 
increase in school absences due to asthma exacerbations in children with asthma, over the 
previous 6 months. No increase in the risk of hospital admission due to asthma 
exacerbations was observed in the children with Arg16Arg genotype (table 4.2.6). 
 
There was a significant increase in the overall asthma exacerbations (OR 1.30; 95% CI 
1.09-1.55 (p= 0.003)) in children with asthma regardless of the asthma treatment steps, per 
copy of Arg16 allele (table 4.2.7). 
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The Glu27Gln genotype did not show any increase in the risk of requirement for the short 
courses of oral steroids due to asthma exacerbations in this population (Table 4.2.8). The 
Glu27Gln genotype did not show any increase in the risk of school absences due to asthma 
exacerbations in this population (Table 4.2.9).   
 
Table 4.2.10 shows the overall effect of the Glu27Gln genotype on the risk of increase in 
hospital admissions due to asthma exacerbations in this population, conditioned on the 
Arg16Gly genotype. Table 4.2.11 shows the overall effect of the Glu27Gln genotype on the 
risk of increase in overall exacerbations of asthma in this population, conditioned on the 
Arg16Gly genotype.   
   
The data in table 4.2.12 demonstrates an increased prevalence of exacerbations in 
individuals per copy of the Arg16 allele in the total population regardless of medication: 
(OR 1.30, 95% CI=1.09-1.55; p=0.003). As the co-dominant model provided the best fit of 
the data based on the highest likelihood ratio obtained for this model, this model was used 
for the remainder of the analysis. 
 
The Arg16 variant did not appear to be associated with general asthma severity as there was 
no difference in the Arg16 allele frequency across the different treatment steps )(table 
4.2.12) (chi-square test 8 d.f. = 5.8, p=0.666). 
In this present study which has been extended to 1182 participants, I observed a significant 
increase in exacerbation risk per copy of the Arg16 allele in participants on treatment step 2 
(regular inhaled corticosteroids and inhaled salbutamol on demand) (Gly/Gly 97/271 
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(36%), Arg/Gly 112/293 (38%), Arg/Arg 47/95 (49%); OR= 1.32; 95%CI=1.04-1.67); 
p=0.02) (table 4.2.12).  
 
I also observed an increase in exacerbation risk per copy of the Arg16 allele on step 3 
(regular inhaled steroids, long-acting β2-agonist salmeterol and inhaled salbutamol on 
demand) (Gly/Gly 25/63 (40%), Arg/Gly 34/65 (52%), Arg/Arg 19/29 (65%); OR= 1.74 
(95%CI=1.09-2.80); p= 0.02) (table 4.2.12). This effect was not observed in participants 
with asthma at steps 0, 1 and 4.  
 
In comparison, this effect was not observed in the Glu27Gln variations (table 4.2.13). Table 
4.2.14 shows the association of homozygous Arg16 status with asthma exacerbations in 
patients on regular salmeterol (combined steps 3 and 4) and those not on regular salmeterol 
(combined steps 0, 1, and 2).  I observed an increased risk of exacerbation in both the 
groups (combined steps 0, 1 and 2: OR= 1.23, 95% CI= 0.99-1.52, p=0.05; and combined 
steps 3 and 4: OR= 1.51, 95%CI=1.05-2.17, p=0.02). Participants in treatment steps 2, 3 
and 4 showed greater use of inhaled short-acting β2-agonists according to need in 
comparison to participants in treatment steps 0 and 1 (odds ratio for daily or greater use 
3.85; 95%CI= 2.86-5.18, p<0.001).The Arg16Arg variant was associated with a greater 
frequency of asthma exacerbations in children with persistent and moderate to severe 
asthma with more frequent use of short-acting β2-agonists (i.e. treatment steps 2, 3 and 4 
combined) in comparison to those with mild asthma (treatment steps 0 and 1) where short-
acting β2-agonist use is less frequent. 
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This data suggested that exposure to β2-agonist per se rather than whether the  
β2-agonist was short or long acting, was associated with increase in the risk of 
exacerbations in children carrying the Arg16 allele. I therefore studied the association of 
the Arg16Gly genotype for asthma exacerbations in individuals on infrequent versus daily 
exposure to salbutamol and/or salmeterol (table 4.2.15). In asthmatic participants taking 
any inhaled β2-agonist less than once a day, there was no effect of Arg16 allele copy on the 
risk of exacerbations. In participants using any inhaled β2-agonist at least once daily (as 
required salbutamol taken at least once daily and/or regular inhaled salmeterol) there is an 
increased risk of asthma-related exacerbations (OR=1.64 (95% CI 1.22-2.20; p=0.001) per 
copy of Arg16 allele.  The interaction term between genotype and daily use of any inhaled 
β agonists (as required salbutamol and/or salmeterol) was significant (p=0.022) (table 
4.2.11).   In the group exposed to β2-agonists daily, the co-dominant model of risk was 
clearly observed with the Arg16Gly heterozygotes having an odds ratio for exacerbations of 
1.63 (95%CI= 1.02-2.60, p=0.04) and the Arg16Arg homozygotes having an odds ratio of 
2.70 (95%CI= 1.46-4.99, p=0.002) when compared to the individuals with the common 
Gly16Gly genotype. 
 
The Arg16 variant had no significant effects on individual measures of pulmonary function 
(FEV1, FVC and PEFR). FEV1/FVC forced expiratory ratio was significantly reduced in 
participants with Arg16Arg genetic status with moderate to severe asthma compared to 
mild asthma (0.84 versus 0.88; p=0.002) (figure 4.2.1) but not in those with the Arg/Gly or 
Gly/Gly genotypes  with moderate to severe asthma  compared to mild asthma (0.89 versus 
0.90; p>0.05). 
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Table: 4.2.1: Demographics of participants for the association study between the β2 
agonist genotype variations and asthma exacerbations (n= 1182) 
 
 
 
Mean (SD) age (years) 
 
10.3 (4.0) (<18=1137; 
≥18= 45) 
Sex (Male/Female) 
 
703/479 
Mean (SD) body mass index 19.1 (4.5) 
 
Mean (SD) PEFR (% of mean predicted) n=915 87.6 (17.8) 
 
Mean (SD) FEV1 (% of mean predicted)  n=915  95.8 (15.5) 
 
Mean (SD) FVC (% of mean predicted)  n=915 92.2 (14.4) 
 
Mean (SD)FEV1/FVC (% of mean predicted)  n=915 102 (0.97) 
 
Atopic eczema (yes/no); n=1182 607/575 (51.4%) 
 
Exposure to smoke (yes/no); n=1182 401/744 (35%) 
 
Arg16Gly genotype distribution; n=1182 Gly16Gly 483 (40.8%), 
Arg16Gly 518 (43.8%), 
Arg16Arg 181(15.3%) 
 
KEY: SD: standard deviation; PEFR: Peak expiratory flow rate; FEV1: Forced expiratory volume in 1 second; 
FVC: Forced vital capacity  
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Table 4.2.2: Medication use and exacerbations of asthma (n= 1182) 
 
 
 
 
 
 
 
 
 
Modified British Thoracic Society (BTS) step of 
asthma treatment* 
0= 39(3.3%); 1= 204 (17.3%); 
2= 660 (56%);  
3= 157 (13.3%); 4= 117 
(10%) 
 
Mean dose of inhaled corticosteroids 
(Beclomethasone diproprionate equivalent) 
432.3 microgram (SEM 12.6) 
Number of children using more than once a week 
‗on demand‘ inhaled short-acting beta agonists  
1044 (79%) 
Inhaled bronchodilator use† 0= 137(11.6%); 1= 827(70%); 
2= 186(15.7%); 3= 31(2.6%) 
School absences (yes/no)over previous 6 months; 
n=1182 
382/ 800 (32.3%) 
Courses of oral steroids (yes/no)over previous 6 
months; n=1182 
263/ 919 (22.3%) 
Hospital admissions (yes/no)over previous 6 
months; n=1182 
157/ 1025 (13.3%) 
Overall asthma exacerbations ‡ (yes/no)over 
previous 6 months; n=1182 
456/ 726 (38.6%) 
 
 
KEY:* Step 0 – no use of inhaled salbutamol on demand within the past month; Step 1 - inhaled salbutamol 
on demand; Step 2 - regular inhaled steroids plus inhaled salbutamol on demand; Step 3 - regular inhaled 
salmeterol plus inhaled steroids with inhaled salbutamol on demand; step 4 - regular inhaled salmeterol plus 
inhaled steroids plus oral montelukast and/or other add-on medications with inhaled salbutamol on demand; 
†Inhaled bronchodilator use: 0= none, 1= occasional (more than once a week and less than daily use), 2= 
daily (200 mcg/ day required for symptom control), 3= excessive use (use of more than one dose of 200 
micrograms/ day for symptom control); ‡Defined as any one of the following in previous 6 months: school 
absences, courses of oral steroids, or hospital admissions  
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Table: 4.2.3: Genotype distributions for codons 16 and 27 (n= 1182) 
 
 
 
 
 
 
 
 
 
 
Polymorphic variations 
 
No. of individuals 
 
Gly16Gly Glu27Glu 
 
232 
 
Gly16Gly Glu27Gln 
 
197 
 
Gly16Gly Gln27Gln 
 
45 
 
Arg16Gly Glu27Glu 
 
3 
 
Arg16Gly Glu27Gln 
 
372 
 
Arg16Gly Gln27Gln 
 
132 
 
Arg16Arg Glu27Glu 
 
0 
 
Arg16Arg Glu27Gln 
 
0 
 
Arg16Arg Gln27Gln 
 
175 
 
Undetermined at position 27 
 
26 
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Table: 4.2.4: Overall effect of Arg16Gly genotype on oral steroid intake due to asthma 
exacerbations, in children and young adults with asthma regardless of treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genotype 
Gly16Gly 
 
 
Arg16Gly 
 
Arg16Arg 
 
Total 
 
OR 
(95% 
CI) 
p value 
 
 
No 
 
 
 
383 
 
404 
 
 
131 
 
918 
 
 
 
1.27 
(1.04-
1.56) 
 
 
 
 
 
 
 
 
 
 
 
0.02 
 
 
 
 
 
 
 
 
 
 
Yes 
 
 
 
 
99 
 
 
 
 
113 
 
 
 
50 
 
 
 
262 
 
 
Total 
 
 
 
482 
 
 
 
517 
 
 
181 
 
 
1180 
 
 
KEY: OR: Odds ratio; CI: Confidence interval 
p values were calculated by binary logistic regression corrected for age, sex, perennial rhinitis, smoking and 
exposure to tobacco smoke. Odds ratio is per copy of the Arg16 allele (additive model). 
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Table: 4.2.5: Overall effect of Arg16Gly genotype on school absences due to asthma 
exacerbations in children and young adults with asthma regardless of treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genotype 
Gly16Gly 
 
 
Arg16Gly 
 
Arg16Arg 
 
Total 
 
OR 
(95% 
CI) 
p 
Value 
 
 
No 
 
 
 
338 
 
355 
 
 
107 
 
800 
 
 
 
1.29 
(1.07-
1.54) 
 
 
 
 
 
 
 
 
 
 
 
0.007 
 
 
 
 
 
 
 
 
 
 
Yes 
 
 
 
 
144 
 
 
 
 
162 
 
 
 
74 
 
 
 
380 
 
 
Total 
 
 
 
482 
 
 
 
517 
 
 
181 
 
 
1180 
 
 
 
KEY: OR: Odds ratio; CI: Confidence interval 
p values were calculated by binary logistic regression corrected for age, sex, perennial rhinitis, smoking and 
exposure to tobacco smoke. Odds ratio is per copy of the Arg16 allele (additive model). 
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Table: 4.2.6: Overall effect of Arg16Gly genotype on hospital admissions due to 
asthma exacerbations in children and young adults with asthma regardless of 
treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genotype 
Gly16Gly 
 
 
Arg16Gly 
 
Arg16Arg 
 
Total 
 
OR 
(95% 
CI) 
p Value 
 
 
No 
 
 
417 452 154 1023  
 
 
1.04 
(0.82-
1.34) 
 
 
 
0.73 
 
 
Yes 
 
 
65 65 27 157 
 
Total 
 
 
 
482 
 
 
 
517 
 
 
181 
 
 
1180 
 
 
KEY: OR: Odds ratio; CI: Confidence interval 
p values were calculated by binary logistic regression corrected for age, sex, perennial rhinitis, smoking and 
exposure to tobacco smoke. Odds ratio is per copy of the Arg16 allele (additive model). 
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Table: 4.2.7: Overall effect of Arg16Gly genotype on overall asthma exacerbations, in 
children and young adults with asthma regardless of treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genotype 
Gly16Gly 
 
 
Arg16Gly 
 
Arg16Arg 
 
Total 
 
OR 
(95% 
CI) 
p Value 
 
 
No 
 
 
310 321 95 726  
 
 
1.30 
(1.09-
1.55) 
 
 
 
 
 
 
 
 
 
 
 
0.003 
 
 
 
 
 
 
 
 
 
 
Yes 
 
 
172 196 86 454 
 
Total 
 
 
 
482 
 
 
 
517 
 
 
181 
 
 
1180 
 
 
KEY: OR: Odds ratio; CI: Confidence interval 
p values were calculated by binary logistic regression corrected for age, sex, perennial rhinitis, smoking and 
exposure to tobacco smoke. Odds ratio is per copy of the Arg16 allele (additive model). 
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Table 4.2.8: Overall effect of Glu27Gln genotype on oral steroid intake in children 
and young adults with asthma across all steps of asthma management conditioned on 
Arg16Gly genotype 
 
 
 
 
 
 Genotype  
Glu27Glu Glu27Gln Gln27Gln Total OR (p 
value) for 
Glu27Gln 
OR (p 
value) for  
Arg16Gly 
No 192 264 442 
 
898 1.11 (0.82-
1.48) 
p =0.50 
1.21 (0.91-
1.61) 
p=0.19 Yes 43 88 127 
 
258 
Total 235 352 569 
 
1156 
 
 
KEY: p values were calculated by binary logistic regression corrected for age, sex, perennial rhinitis, smoking 
and exposure to tobacco smoke, using a co-dominant model. Odds ratios are per genotypic step 
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Table 4.2.9: Overall effect of Glu27Gln genotype on school absences due to asthma 
exacerbations, in children and young adults with asthma across all steps of asthma 
management conditioned on Arg16Gly genotype 
 
 
 
 
 
 Genotype  
Glu27Glu Glu27Gln Gln27Gln Total OR (p 
value) for  
Glu27Gln 
OR (p 
value) for 
Arg16Gly 
No 167 224 393 
 
784 1.08 (0.83-
1.39) 
p=0.57 
1.24 (0.96-
1.59) 
p=0.10 
 
Yes 68 128 176 
 
372 
Total 235 352 569 
 
1156 
 
KEY: p values were calculated by binary logistic regression corrected for age, sex, perennial rhinitis, smoking 
and exposure to tobacco smoke, using a co-dominant model. Odds ratios are per genotypic step 
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Table 4.2.10: Overall effect of Glu27Gln genotype on hospital admissions due to 
asthma exacerbations, in children and young adults with asthma across all steps of 
asthma management conditioned on Arg16Gly genotype 
 
 
 
 
 Genotype  
Glu27Glu Glu27Gln Gln27Gln Total OR (p 
value) for  
Glu27Gln 
OR (p value) 
for 
Arg16Gly 
No 207 303 492 1002 1.18 (0.83-
1.66) 
p =0.35 
0.95 
(0.68-1.34) 
p =0.79 
 
Yes 28 49 77 154 
Total 235 352 569 1156 
 
KEY: p values were calculated by binary logistic regression corrected for age, sex, perennial rhinitis, smoking 
and exposure to tobacco smoke, using a co-dominant model. Odds ratios are per genotypic step 
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Table 4.2.11: Overall effect of Glu27Gln genotype on overall asthma exacerbations, in 
children and young adults with asthma across all steps of asthma management 
conditioned on Arg16Gly genotype 
 
 
 
 
 Genotype  
Glu27Glu Glu27Gln Gln27Gln Total OR (p 
value) for 
Glu27Gln 
OR (p 
value) for  
Arg16Gly 
No 153 200 357 
 
710 1.06(0.82-
1.36) 
p =0.65 
 
1.27 (0.99-
1.63) 
p=0.06 Yes 82 152 212 
 
446 
Total 235 352 569 
 
1156 
 
 
KEY: p values were calculated by binary logistic regression corrected for age, sex, perennial rhinitis, smoking 
and exposure to tobacco smoke, using a co-dominant model. Odds ratios are per genotypic step 
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Table: 4.2.12: Association of asthma exacerbations and Arg16Gly genotype variations 
according to the steps of management of asthma (n=1182) 
 
 
 
Asthma 
treatment 
steps 
Genotype Exacerbations over previous 6 months OR (95%CI) 
 p value 
No Yes Total 
Step 0 Gly16Gly  11 2 13 0.62 (0.09-4.22) 
p=0.63 Gly16Arg 19 1 20 
Arg16Arg 5 1 6 
Total 35 4 39 
Step 1 Gly16Gly 70 19 89 1.02 (0.57-1.83) 
p=0.93 
Gly16Arg 71 17 88 
Arg16Arg 23 4 27 
Total 164 40 204 
Step 2 Gly16Gly 174 97 271 1.32 (1.04-1.67) 
p=0.02 
Gly16Arg 181 112 293 
Arg16Arg 48 47 95 
Total 403 256 659 
Step 3 Gly16Gly 38 25 63 1.74 (1.09-2.80) 
p=0.02 Gly16Arg 31 34 65 
Arg16Arg 10 19 29 
Total 79 78 157 
Step 4 Gly16Gly 16 26 42 1.41 (0.77-2.55) 
p=0.26 
Gly16Arg 19 32 51 
Arg16Arg 8 15 23 
Total 43 73 116 
 
KEY: p values were calculated by binary logistic regression corrected for age, sex, perennial rhinitis, smoking 
and exposure to tobacco smoke, using a co-dominant model- that is, a gene/dosage effect for the Arg16Arg 
variant. Odds ratios are per copy of the Arg16 allele.  There was no difference in the distribution of the Arg16 
variant between the treatment steps (chi-square test 8 d.f. = 5.8, p=0.666) 
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Table 4.2.13: Association of asthma exacerbations and Glu27Gln genotype variations 
according to the steps of management of asthma, conditioned on Arg16Gly genotype 
 
 
 
 
  
Asthma 
treatment 
steps 
Genotype Exacerbations over previous 6 
months 
OR (P value) 
No Yes Total 
Step 0 Glu27Glu 5 1 6 0.17 (0.11) 
Glu27Gln 16 2 18 
Gln27Gln 12 1 13 
Total 33 4 37 
Step 1 Glu27Glu 32 11 43 1.50 (0.33) 
Glu27Gln 90 17 107 
Gln27Gln 38 11 49 
Total 160 39 199 
Step 2 Glu27Glu 90 48 138 0.99 (0.95) 
Glu27Gln 199 125 324 
Gln27Gln 107 80 187 
Total 396 253 649 
Step 3 Glu27Glu 20 8 28 1.30(0.41) 
Glu27Gln 32 32 64 
Gln27Gln 25 34 59 
Total 77 74 151 
Step 4 Glu27Glu 6 11 17 0.74 (0.48) 
Glu27Gln 19 36 55 
Gln27Gln 17 26 43 
Total 42 76 115 
 
 
KEY: p values were calculated by binary logistic regression corrected for age, sex, perennial rhinitis, smoking 
and exposure to tobacco smoke, using a co-dominant model. Odds ratios are per genotypic step 
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Table 4.2.14: Effect of Arg16Gly genotype status on the proportion of patients 
developing asthma exacerbations according to salmeterol treatment status. 
  
 
 
 
 
 
 
 
Treatment Genotype Total exacerbations OR (95% CI) 
(p values) 
No Yes Total 
No Salmeterol Gly16Gly 255 118 373 1.23 (0.99-1.52) 
p=0.05 
Gly16Arg 271 130 401 
Arg16Arg 76 52 128 
Total 602 300 902 
Salmeterol 
treated. 
Gly16Gly 54 51 105 1.51 (1.06-2.17) 
p=0.02 
Gly16Arg 50 66 116 
Arg16Arg 18 34 52 
Total 
 
122 151 273 
 
 
KEY: p values were calculated by binary logistic regression corrected for age, sex, perennial rhinitis, smoking 
and exposure to tobacco smoke, using a co-dominant model. Odds ratios are per copy of the Arg16 allele. 
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Table 4.2.15: Association and drug-genotype interaction of Arg16Gly genotype with 
asthma exacerbations in children with, and without, daily exposure to β2 agonists.  
 
 
 
  
Exacerbations  NO YES Total OR (95% CI) 
p value 
Salbutamol/salmeterol  
usage less than once 
per day. 
Gly16Gly 228 100 328 1.08 (0.85-
1.36) 
p =0.525* 
 
 
 
1.27 (0.77-
2.08) 
p =0.353** 
Arg16Gly 241 98 339 
Arg16Arg 69 37 106 
 
Total 538 235 773 
 
Exacerbations  NO YES Total  
Daily use of any β 
agonist (as required 
salbutamol and/or 
salmeterol) 
Gly16Gly 81 69 150 
 
1.64 (1.22-
2.20) 
p =0.001* 
 
 
2.68 (1.46-
4.94)  
p =0.002** 
Arg16Gly 80 97 177 
 
Arg16Arg 25 49 74 
 
Total 186 215 401 
 
Test for interaction between genotype and 
daily use of any β agonist on exacerbations. 
p =0.022* 
p =0.049** 
  
 
KEY: p values were calculated by binary logistic regression corrected for age, sex, perennial rhinitis, smoking 
and exposure to tobacco smoke, using a co-dominant model. *Odds ratios (OR, 95%CI) and p values are 
shown for the co-dominant model (Odds ratio per copy of the Arg16 allele). **Odds ratios (OR, 95%CI) and 
p values are shown for the comparison of Arg16 homozygotes versus the Gly16 homozygotes.  
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Figure 4.2.1: Association of airway obstruction measured as FEV1/FVC and β2 
adrenergic receptor gene variations in children with mild (treatment steps 0 and 1) 
and moderate to severe (treatment steps 2, 3, 4) asthma 
 
 
 
 
 
 
  
 
KEY: FEV1: Forced expiratory value at 1 second; FVC: Forced vital capacity 
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Chapter 3 
 
Effects Of Filaggrin Null Mutations In Asthma Exacerbations  
 
The demographic characteristics of the children who participated in the study to explore the 
association between FLG null mutations and asthma exacerbations are described in table 
4.3.1. Table  4.3.2 describes the management of asthma as per the modified BTS guideline 
steps, inhaled bronchodilator use, filaggrin genotypes and measures of asthma 
exacerbations in the participants. Figure 4.3.1 describes the proportion of the study 
population with FLG null allele on the treatment steps of asthma management. 
 
Figure 4.3.2 demonstrates frequencies of individuals with FLG null mutations with and 
without asthma exacerbations over the previous 6 months. Amongst the participants 
without an asthma exacerbation, only 11.2% had an FLG null mutation. 16.8% of 
participants with asthma exacerbation had an FLG null mutation. The allele frequencies of 
the FLG mutations R501X and 2282del4 in the children with asthma were increased 
relative to the Tayside population.  
 
Table 4.3.3 describes the association between the filaggrin null mutations and asthma 
exacerbations. Asthma exacerbations were found to be significantly increased in children 
with FLG mutation R501X and the combined genotype. The contingency analysis (Table 
4.3.3) shows that the heterozygous and homozygous genotypes for the R501X mutation, 
and the combined genotype, were associated with higher risk for exacerbations of asthma. 
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This is significant for the R501X mutation (p= 0.009) and the combined genotype (p= 
0.021; Table: 4.3.3). 35% (301/859) of FLG wild- type participants were prone to 
exacerbations, a significantly greater proportion 51% (35/68) of FLG null allele carriers 
with asthma suffered from exacerbation of their asthma. Hence there was a 1.97- fold 
greater risk (95% CI, 1.19- 3.22) of suffering from exacerbation of asthma in  FLG null 
allele carriers in comparison to FLG wild- type participants with asthma.  
  
Table 4.3.5 shows that there was a significant increased risk in asthma-related school 
absence in participants carrying R501X mutation (p= 0.041). 30.0% (261/862) and 19.5% 
(173/ 887) of FLG wild type participants were absent from school or required oral steroids 
due to worsening of their asthma. This compares with 42.6% (29/68) and 31.4% (22/70) of 
FLG null allele carriers experiencing school absences or requiring a course of oral steroids 
over the previous 6 months. There was a 1.71-fold risk (95% CI, 1.04- 2.83) of school 
absences due to asthma and a 1.89- fold risk (95% CI, 1.11-3.21) of requiring oral steroids 
to treat exacerbations in this population. 
 
No such association was observed in relation to hospital admission due to asthma 
exacerbations over the previous 6 months of collection of the data (table 4.3.6).  
 
Figure 4.3.3 describes the proportion of the total study population with asthma 
exacerbations, irrespective of their genotype, in the previous 6 months across the treatment 
steps of asthma management according to the modified BTS guidelines. The participants on 
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step 3 of asthma management constituted the maximum proportion (48%) of children with 
asthma exacerbations over the previous 6 months. This was followed by participants on 
step 2 (37%). 
 
On further analysis, exacerbations of asthma were found to be significantly increased (OR 
1.83, 95% CI, 1.013- 3.29; p= 0.045) in individuals with the FLG null alleles compared to 
FLG wild type only for asthma treatment step 2 (regular inhaled steroids plus inhaled short-
acting beta agonists according to need) although a similar trend with greater risk with FLG 
null alleles compared to FLG wild type was observed for treatment steps 3 and 4 
(participants on regular inhaled long-acting beta agonists with or without montelukast, in 
addition to regular inhaled steroids and inhaled short-acting β-agonists according to need) . 
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Table: 4.3.1: Demographic characteristics of participants with asthma for the study of 
association between asthma exacerbations and filaggrin mutations (n=1135) 
 
 
 
 
 
 
 
Age Range, 3-22 (mean, 10.3; SD, 
5.1); (<18=1091; ≥18= 44) 
Sex (males: females) 671 (59.1%): 464 (40.9%) 
With eczema: without eczema (n=1125) 580:544 
Family history of asthma and eczema 
Paternal asthma (yes/ no) 219/ 901 (19.6%) 
Paternal eczema (yes/ no) 82/ 1037 (7.3%)) 
Maternal asthma (yes/ no) 269/ 850 (24.0%)) 
Maternal eczema (yes/ no) 162/ 958 (14.5%) 
Mean percent predicted FEV1 (SD) (n=863) 95.8 (15.6) 
Mean percent predicted FVC (SD) (n=862) 92.2 (14.5) 
Mean FEV1/ FVC (SD) (n=880) 89.3 (14.8) 
 
KEY: SD: standard deviation; PEFR: Peak expiratory flow rate; FEV1: Forced expiratory volume in 1 second; 
FVC: Forced vital capacity  
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Table 4.3.2: Medication use, genotypes and asthma exacerbations 
 
Modified BTS asthma treatment steps 
†(n=1116) 
Step 0=69; Step 1=189;  
Step 2= 610; Step 3=149;  
Step 4=99 
Inhaled bronchodilator use (n=1111) 
0= None 
 
144 
1= Occasional 
 
763 
2= Daily 
 
178 
3= Excessive 
 
26 
R501X AA: Aa/ aa (%) 
 
895(92.6%): 72 (7.4%) 
2282del4 AA: Aa/ aa (%) 
 
856 (94.3%): 52 (5.7%) 
Combined genotype AA: Aa/ aa (%) 
 
774 (86.7%): 119 (13.3%) 
School absences (yes/ no) over previous 6  
 
Months 
339/ 753 (31%) 
Courses of oral steroids (yes/ no) over previous  
 
6 months 
228/ 895 (20.3%) 
Hospital admissions (yes/ no) over previous 6 
 
 months due to exacerbations  
125/ 998 (11.1%) 
Overall asthma exacerbations *(yes/ no) over  
 
previous 6 months 
394/ 694 (36.2%) 
 
KEY: †Step 0 – no use of inhaled salbutamol on demand within the past month; Step 1 - inhaled salbutamol 
on demand; Step 2 - regular inhaled steroids plus inhaled salbutamol on demand; Step 3 - regular inhaled 
salmeterol plus inhaled steroids with inhaled salbutamol on demand; step 4 - regular inhaled salmeterol plus 
inhaled steroids plus oral montelukast and/or other add-on medications with inhaled salbutamol on demand; 
aa: Homozygous R501X or 2282type or compound heterozygous genotype; Aa: Heterozygous genotype for 
either R501X or 2282del4; AA: Wild-type FLG genotype for R501X and 2282del4 mutation; *Defined as any 
one of the following in previous 6 months: school absences, courses of oral steroids, or hospital admissions  
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Figure 4.3.1: The proportion of participants with FLG null allele frequency across the 
treatment steps of the management of asthma 
 
 
KEY: Step 0 – no use of inhaled salbutamol on demand within the past month; Step 1 - inhaled salbutamol on 
demand; Step 2 - regular inhaled steroids plus inhaled salbutamol on demand; Step 3 - regular inhaled 
salmeterol plus inhaled steroids with inhaled salbutamol on demand; step 4 - regular inhaled salmeterol plus 
inhaled steroids plus oral montelukast and/or other add-on medications with inhaled salbutamol on demand 
 
 
 
Figure 4.3.2: The frequencies of individuals with FLG null mutations with and 
without asthma exacerbations over the previous 6 months. 
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Table 4.3.3: Contingency table for the filaggrin genotype (co-dominant and mutant 
variants) versus exacerbations of asthma.  
 
 
 
 
 Yes No Total p-value 
(one 
tailed) 
p Value 
(two 
tailed) 
Odds ratio 
(95% CI) 
R501X AA 301 558 859 0.006 0.009 1.97 
(1.19-3.23) Aa/aa 35 33 68 
Total 336 591 927 
2282del4 AA 295 526 821 0.438 0.764 1.09 
(0.61- 1.97) Aa/aa 19 31 50 
Total 314 557 871 
Combined 
genotype 
AA 257 486 743 0.013 0.021 1.61 
(1.08-2.40) Aa/aa 52 61 113 
Total 309 547 856 
 
 
KEY: aa: Homozygous R501X or 2282type or compound heterozygous genotype; Aa: Heterozygous 
genotype for either R501X or 2282del4; AA: Wild-type FLG genotype for R501X and 2282del4 mutation; 
CI: Confidence interval; Exacerbation was measured as school absence and/or asthma related hospital 
admissions and/or use of short courses of oral steroids. 
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Table: 4.3.4: Contingency table for the filaggrin genotype (co-dominant and mutant 
variants) versus short courses of oral steroids for treatment of asthma exacerbations 
in the previous 6 months 
 
 
 
 
 
 
 
 Yes No Total p-value 
(one 
tailed) 
p-value 
(two 
tailed) 
Odds ratio 
(95% CI) 
R501X AA 173 714 887 
 
0.016 0.021 1.89 
(1.11-3.22) 
Aa/aa 22 48 70 
 
Total 195 762 957 
 
2282del4 AA 167 680 847 
 
0.203 0.366 1.39 
(0.73- 2.67) 
Aa/aa 13 38 51 
 
Total 180 718 898 
 
Combined 
genotype 
AA 145 622 767 
 
0.014 0.025 1.71 
(1.09-2.65) 
Aa/aa 33 83 116 
 
Total 178 705 883 
 
 
 
KEY: aa: Homozygous R501X or 2282type or compound heterozygous genotype; Aa: Heterozygous 
genotype for either R501X or 2282del4; AA: Wild-type FLG genotype for R501X and 2282del4 mutation; 
CI: Confidence interval 
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Table: 4.3.5: Contingency table for the filaggrin genotype (co-dominant and mutant 
variants) versus asthma-related school absences in the previous 6months 
 
 
 
 
 
 
 Yes No Total p-value 
(one 
tailed) 
p-value 
(two 
tailed) 
Odds ratio 
(95% CI) 
R501X AA 261 601 862 0.026 0.041 1.71 
(1.04-2.83) 
Aa/aa 29 39 68 
Total 290 640 930 
2282del4 AA 259 565 824 0.173 0.345 0.69 
(0.35-1.34) 
Aa/aa 12 38 50 
Total 27 603 874 
Combined 
genotype 
AA 228 518 746 0.229 0.445 1.19  
(0.79-1.82) 
Aa/aa 39 74 113 
Total 267 592 859 
 
 
KEY: aa: Homozygous R501X or 2282type or compound heterozygous genotype; Aa: Heterozygous 
genotype for either R501X or 2282del4; AA: Wild-type FLG genotype for R501X and 2282del4 mutation; 
CI: Confidence interval 
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Table: 4.3.6: Contingency table for the filaggrin genotype (co-dominant and mutant 
variants) versus asthma-related hospital admissions in the previous 6months 
 
 
 
 
 
 
 Yes No Total p-value 
(one 
tailed) 
p-value 
(two 
tailed) 
Odds ratio 
(95% CI) 
R501X AA 94 792 886 0.337 0.548 1.24 
(0.59-2.58) 
Aa/aa 9 61 70 
Total 103 853 956 
2282del4 AA 89 757 846 0.374 0.812 0.72  
(0.25-2.06) 
Aa/aa 4 47 51 
Total 93 804 897 
Combined 
genotype 
AA 80 686 766 0.453 0.748 1.08 
(0.58-2.01) 
Aa/aa 13 103 116 
Total 93 789 882 
 
 
KEY: aa: Homozygous R501X or 2282type or compound heterozygous genotype; Aa: Heterozygous 
genotype for either R501X or 2282del4; AA: Wild-type FLG genotype for R501X and 2282del4 mutation; 
CI: Confidence interval 
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Figure 4.3.3: The proportion of participants with exacerbations of asthma across the 
steps of management of asthma 
 
 
 
 
 
 
KEY: Step 0 – no use of inhaled salbutamol on demand within the past month; Step 1 - inhaled salbutamol on 
demand; Step 2 - regular inhaled steroids plus inhaled salbutamol on demand; Step 3 - regular inhaled 
salmeterol plus inhaled steroids with inhaled salbutamol on demand; step 4 - regular inhaled salmeterol plus 
inhaled steroids plus oral montelukast and/or other add-on medications with inhaled salbutamol on demand
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Figure 4.3.4: Comparison of asthma exacerbations between children and young adults 
with and without FLG null alleles across the treatment steps of asthma    
 
 
 
 
 
 
 
KEY: *p=0.045; Step 0 – no use of inhaled salbutamol on demand within the past month; Step 1 - inhaled 
salbutamol on demand; Step 2 - regular inhaled steroids plus inhaled salbutamol on demand; Step 3 - regular 
inhaled salmeterol plus inhaled steroids with inhaled salbutamol on demand; step 4 - regular inhaled 
salmeterol plus inhaled steroids plus oral montelukast and/or other add-on medications with inhaled 
salbutamol on demand 
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Chapter 4  
 
Effects of filaggrin defects on epithelial permeability 
 
The demographic characteristics of the participants participated in the pilot study to 
determine the effects of filaggrin defects on the epithelial permeability in skin and gut are 
described in table 4.4.1. 10 children with asthma with or without eczema were recruited as 
well as 14 children as control population. This was not a blinded study and the control 
group was not pre-genotyped. 
 
Figure 4.4.1 shows the individual measurements of the transepidermal water loss in g/hm
2 
of the asthmatic children with filaggrin mutation (median ±MAD= 11.3 ± 1.75g/hm
2
, n=10) 
and the control group (median ±MAD= 7.45±1.38 g/hm
2
, n=14). Transepidermal water loss 
in the asthmatic children heterozygous for the filaggrin null alleles was significantly 
increased (p=0.02, Mann Whitney rank sum test). One child in this group had very high 
measurement (33g/hm
2
) and therefore the median was recalculated omitting this outlier 
(10.8 ± 1.8g/hm
2
, n=9). The transepidermal water loss of this group was still significantly 
higher than that of the control group (p=0.044, Mann Whitney rank sum test). 
 
The percentages of ingested lactulose recovered in the urine of the control group 
(median±MAD= 0.18±0.006%, n=8) were not different from those of the children 
heterozygous for the filaggrin null alleles (median±MAD=0.20±0.006%, n=8, p=not 
significant Mann Whitney rank sum test). The percentages of ingested mannitol recovered 
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in the urine were (11.9±7.8%, n=8) in the control group, not different from those of the 
children heterozygous for the filaggrin null alleles (16.3±7.5%, n=8, p=not significant 
Mann Whitney rank sum test). The lactulose/ mannitol ratio has been plotted for each 
individual in figure 4.4.2. 
Lactulose: mannitol ratios of the control group (0.013±0.010) were also not different from 
the ratios of the children heterozygous for the filaggrin null alleles (0.014±0.007, p=not 
significant, Mann Whitney rank sum test).  
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Table 4.4.1: Characteristics of controls and participants with filaggrin mutations for 
the epithelial permeability pilot study  
 
 
 
 
 
 
Characteristic Asthma patients with 
FLG mutations (n=10) 
Control group (n=14) 
Eczema 7 (70%) 0 
Age ± SD 10.9 ±3.2 9.9 ± 2.9 
Sex (males: females) 6: 4  8:6 
R501X AA: Aa/ aa  1:9 Not applicable 
2282del4 AA: Aa/ aa  9:1 Not applicable 
Combined genotype AA: Aa/ 
aa  
1: 9 Not applicable 
Paternal asthma (yes/ no) 3/7(30%) None 
Paternal eczema (yes/ no) 2/ 8 (10%) None 
Maternal asthma (yes/ no) 3/7 (30%) None 
Maternal eczema (yes/ no) 3/7 (30%) None 
 
KEY: aa: Homozygous R501X or 2282type or compound heterozygous genotype; Aa: Heterozygous 
genotype for either R501X or 2282del4; AA: Wild-type FLG genotype for R501X and 2282del4 mutation 
105 
 
Figure 4.4.1: Transepidermal water loss in the children heterozygous for the FLG null 
allele with asthma and the control group 
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Figure 4.4.2: Excreted lactulose/mannitol ratio in the children heterozygous for the 
FLG null allele with asthma and the control group 
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                                                    SECTION V 
 
DISCUSSION 
 
Chapter 1  
 
BREATHE Is A Large Cross-Sectional Study In Children’s Asthma With Genotype 
And Phenotype Data 
 
For the first time, a large cross-sectional study has been conducted in a population of 
children and young adults with asthma in primary and secondary care in the UK, in terms 
of relevant history, medication use and exacerbations. The study of genetic variations in 
relation to response to medication in asthma will allow us to gain key information 
regarding which patients are best suited for a particular therapeutic agent and which 
patients may be at risk for serious potentially life-threatening complications from standard 
treatment regimens.  
 
Characterizing persistent users of asthma medication is important to understand prescribing 
of asthma medication in children
118
. However, studies performed to assess trends in 
paediatric asthma drug prescribing in the UK, have shown that the increase in the number 
of combination inhalers prescribed is not consistent with the guideline recommendations
32
 
and off-label prescribing for children with asthma in primary care was found to be 
108 
 
associated with worse levels of self-reported asthma control
34
. Children and young adults 
with asthma also receive treatment not in accord with current licences and evidence-based 
recommendations and, as such, may be at risk of adverse outcomes
33
. A previous study 
highlights the over-use of high-dose inhaled corticosteroids, the under-use and 
inappropriate use of add- on therapy, and the use of very high and potentially dangerous 
doses of inhaled corticosteroids in a minority of children
33
.  
 
Marked variability in severity of symptoms, natural history, risks of adverse outcomes, 
pathologic characteristics, and response to therapy have been observed in asthma
5
. A 
striking absence of correlation is observed among the pathologic, physiologic, and clinical 
manifestations of asthma in adults
5
. Lung function tends to correlate poorly with clinical 
outcomes, and there is only modest correlation between clinical outcomes. Understanding 
the relationship between these factors may also be complicated by the variability of 
outcomes and the lack of correlation between them.  
 
The BREATHE database of children and young adults with asthma contains information on 
patient genotype, environmental factors contributing to asthma, and clinical asthma 
severity. Children‘s asthma has distinctive features and does not necessarily lead to asthma 
in adult life. Several novel observations on the gene-environmental interactions associated 
with childhood asthma, obtained from the BREATHE study have been published
22-24,103-104
. 
The results of these preliminary studies in children have allowed me to proceed to 
hypothesis-based research that will explore the relationships between phenotypic asthma 
and specific genotypes. A recent editorial in Nature Genetics expressed concern about 
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quality of many published case/ control studies that had undermined public confidence 
when results were first publicised, and then rapidly followed by non-replication or 
refutation
119
. It suggested the optimal condition for association studies including large 
sample sizes, small p values, and plausible associations that make biological sense. 
Furthermore, findings must be supported by independent replication, with associations 
combining family- based and population- based analysis, with an odds ratio and/ or 
attributable risk that is high. We have been able to replicate gene-environmental 
associations in relation to asthma, in a paediatric population through several studies 
originating from the BREATHE database
21, 104
.  
 
The database captures a window in the participants‘ life (six months) and they may have 
had changes to treatment just prior to the data acquisition (particularly if they have only 
recently attended the clinic). This might account for some of the findings in relation to 
children and young adults with asthma on treatment step 4. This is a major limitation of the 
study. However, for simplicity and better parental recall of events, the history was taken 
and limited only for the previous six months.    
 
The study is now being extended to Sussex with the aim of creating a larger database 
across the UK. The aim is to recruit more participants over the next few years and study 
similar genetic variations in relation to clinical outcomes. The Sussex database would be 
subsequently merged with the Scottish database giving us information from a bigger 
population. The diversity in ethnic, cultural and environmental background of the 
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population might help in the exploration of several other associations in asthma phenotypic 
variation and specific genotypes.  
 
Chapter 2  
 
Adrenergic β2-receptor Genotype Predisposes To Exacerbations In Steroid-Treated 
Asthmatics On Frequent Salbutamol Or Salmeterol  
 
My study (tables 4.2.1-4.2.15; figure 4.2.1) shows for the first time that there is an increase 
in risk of exacerbations per copy of Arg16 allele in children and young adults with asthma 
on frequent (once daily or more) as required doses of inhaled salbutamol (table 4.2.15). 
This effect is not observed in participants with asthma who are not exposed to β2-agonist on 
a daily basis. The study also extends the previous findings of an increase in the risk of 
exacerbations per copy of Arg16 allele in children and young adults with asthma on the 
regular long-acting β2-agonist salmeterol. The number of subjects on salmeterol in the 
previous paper was 164 and the group studied in this thesis comprises 273 individuals on 
salmeterol.  
 
I have only investigated two of the SNPs in the ADRB2 gene. Other haplotypes of the 
ADRB2 gene have been described
64, 120
. However, a closer study of the haplotype data show 
that only 3 of the haplotypes are found in relevant numbers in the Caucasian population and 
these are completely tagged by codon 16 and codon 27
64,120
. It is of particular note that the 
promoter gene variations are in complete linkage disequilibrium with the Arg16 variant. 
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This linkage disequilibrium is exclusively relevant in the Caucasian population. Therefore 
in practical terms, in a study such as ours where the analysis exclusively involves 
Caucasians, it is only possible to study the association of the 16/27 diplotypic variation 
with clinical outcomes. However, the possibility remains that associations with the Arg16 
variant may only be due to an uncharacterised and tightly linked causal variant. 
 
Both retrospective and prospective analyses of data from a number of randomized 
controlled trials have demonstrated the adverse effects of the Arg16 variant on pulmonary 
function (peak flow rates
60,61,65
, FEV1
60,61
), asthma symptoms
60,65
, methacholine 
responsiveness and exacerbations
61,71,121
  and ‗reliever‘ bronchodilator use60  in adults with 
asthma on regular short-acting β2-agonists. Inhaled short-acting β2-agonists used on an ‗on 
demand‘ basis constitute one of the most commonly prescribed asthma medications in the 
world
18
. This method of use results in a very different pattern of administration of short-
acting β2-agonists, as compared to the regular use of this medication, with short-acting β2-
agonists typically being used prior to activity (e.g. football), exposure to cold (e.g. going to 
school in the early morning), or as frequent doses to afford relief during developing asthma 
exacerbations.  
 
Importantly, the interaction of Arg16 status with inhaled salbutamol on exacerbation risk is 
observed in a population who are not taking regular doses of inhaled salbutamol that may 
be comparable to regular qid administration. 70% of the population on treatment steps 2, 3 
and 4 were using less than one daily dose (200 micrograms/ day) of inhaled salbutamol. 
Only 3% of the population was using inhaled salbutamol several times daily (classified as 
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‗3‘ or ‗excessive‘: this represents the use of more than one dose of 200 micrograms / day 
for the control of symptoms). Against this background of relatively sparse ‗on demand‘ 
inhaled short-acting β2 agonist administration, I have identified a significant deleterious 
effect on asthma exacerbations per copy of Arg16 allele (table 4.2.15). The interaction 
between genotype and daily use of any inhaled β2-agonists (as required salbutamol and/or 
salmeterol) had a significant effect on the risk of asthma exacerbations (p=0.022) (table 
4.2.15).    
 
I have also identified a significant increase in risk of exacerbations in children and young 
adults with mild persistent asthma (i.e., receiving inhaled steroids with inhaled short-acting 
β2-agonists according to need) per copy of Arg16 allele (table 4.2.12). No similar 
associations were observed in mild intermittent asthmatics (where inhaled salbutamol alone 
controls intermittent symptoms or where there has been no requirement for inhaled 
salbutamol within the past month) (table 4.2.12). Indeed, this increased risk per Arg16 
allele copy was also present in step 3 patients who were also taking regular long-acting β2-
agonists (13.3% of the overall population) (table 4.2.12). However, in step 4 patients 
(receiving montelukast in addition to regular long-acting β2-agonists, inhaled steroids and 
salbutamol according to need; 9.9% of the overall population), there was no increase in the 
risk of exacerbations per Arg16 allele copy; despite a higher exposure to short-acting β2-
agonists (table 4.2.12). There was a significant increased risk of exacerbations in the 
asthmatics when steps 3 and 4 were combined together (OR= 1.51 (95% CI=1.06-2.17), 
p=0.02) (table 4.2.14). One possible explanation for this apparent disconnect (table 4.2.12) 
between the genotype associations for steps 3 and 4 could be the concomitant use of 
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montelukast, or the use of oral steroids (treatment step 3: 34%, treatment step 4:42%) or 
higher dose of inhaled steroids (treatment step 3: 533 microgram , treatment step 
4:561microgram BDP equivalent), the latter protecting against β agonist induced down-
regulation and desensitisation via the glucocorticoid response element on the ADRB2 gene, 
while the former conferring non steroidal anti-inflammatory protection
122
. 
 
Previous observations had shown an increased hazard for exacerbations per copy of Arg16 
allele in young asthmatics, with a particular effect of regular inhaled salmeterol on this 
increase in risk
21
. Now that I have doubled our study size, previous effects remain 
consistent. However the effect has not become more significant with greater numbers. It is 
felt, however, that the increased hazard for exacerbations per copy of Arg16 allele in 
asthmatics on salmeterol, observed in the previous study and subsequently in this extended 
study, is a true effect. This is because, in the previous study, the children were mostly 
recruited from the secondary care setting and were on higher steps of asthma management 
(40% of study population on modified BTS step 3 and above)
 18
. When the study was 
extended, I recruited mainly from the primary care setting, and a smaller proportion of the 
new recruits are on inhaled salmeterol (in the combined analysis 23% of the study 
population is on modified BTS step 3 and above). Hence a smaller proportion of the overall 
participants are on salmeterol in the extended analysis, in comparison to the previous 
work
21
. This accounts for the observation that while the effect is consistent, it has not 
become any stronger with the increase of numbers due to a lack of power in step 4.The 
strategy for recruiting participants from primary care to recruit more patients on inhaled 
short-acting β2 agonists on demand and not regular inhaled long-acting β2 agonists was 
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guided by the hypothesis that I primarily wished to test for this study, which is that inhaled 
short acting β2-agonists interact with the Arg16 genotype to increase exacerbation risk and I 
wished to specifically recruit a large population of asthmatics on inhaled short-acting β2-
agonists on demand who were not exposed to regular inhaled long-acting β2 agonists to 
fulfil this goal.  
I have further demonstrated that there is an increase in risk of the individual constituents of 
the asthma exacerbation score - school absences and requirement for courses of oral 
steroids – per copy of the Arg16 allele, over a 6-month period of reporting, in addition to 
the overall effect on asthma exacerbations as has been reported in our previous analysis 
(tables 4.2.3, 4.2.4, 4.2.6).These individual measures represent different aspects of asthma 
exacerbations that have different effects on children and young adults in the community. 
School absences have an impact on the children and young adults‘ education and work, and 
oral steroid courses represent the use of primary care whereas hospital admissions represent 
the impact on secondary care services. Therefore these findings appear to have a greater 
relevance for the burden of asthma in the community and primary care than hospital 
settings.   
 
The observation of an adverse effect per copy of the Arg16 allele of ‗on demand‘ short 
acting β2-agonists on asthma exacerbation risk raises a further question. As patients on 
inhaled long-acting β2-agonists are also on short-acting β2-agonists, what proportion of the 
adverse effect of increased risk of exacerbations in the ‗real-life‘ scenario results through 
the use of long-acting, in comparison to the use of short-acting, β2-agonists? This question 
may be resolved through a study that involves the randomisation of asthmatic carrying the 
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Arg16 allele who are on regular salmeterol to comparator arms of ‗reliever‘ medication, 
short-acting β2-agonist versus ipratropium bromide, with risk of asthma exacerbations as 
the primary outcome measure. Another strategy might be to randomise patients carrying the 
Arg 16 allele to receive either salmeterol or montelukast as add on to inhaled 
corticosteroids, with salbutamol reliever in both arms, on the basis that any potential 
adverse effect of salbutamol could be seen in both randomised arms.  
 
The study participants used inhaled short-acting β2 agonists as reliever and did not use non 
β2 agonists as reliever medication for their asthma. Hence, I cannot provide the data in this 
study to address the hypothesis that the use of relievers that do not act via the β2 receptor 
pathway is not associated with the deleterious effects that have been reported with inhaled 
β2 agonist relievers. This is a major limitation of the study. Hence, as these necessary 
controls are missing, it is too early to draw conclusions in this area of research. Therefore, 
while these data are of interest, a proper study involving a non β2 reliever is now required. 
This could involve either of two strategies. Firstly, if I could identify a population of 
asthmatics with significant use of non- β2 relievers, I could compare the interactions of the 
Arg16 genotype with inhaled β2 agonist reliever use versus non β2 agonist reliever use. 
Alternatively, it could involve a strategy for the prospective randomisation of a population 
of asthmatics carrying the Arg16 genotype to inhaled β2 agonist versus non β2 agonist 
reliever therapy with an exploration of the hypothesis that there is an increased risk of 
asthma exacerbations in participants on inhaled β2 agonists in comparison to participants on 
non β2 agonists. 
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A recent analysis of two separate studies performed on adults (mean age of participants 
around 40 years for both studies) has failed to demonstrate a role for Arg16 genotype on 
clinical outcomes including exacerbations, pulmonary function, and asthma control 
measures in patients receiving inhaled long-acting β2-agonists
123
. However, the selection 
criteria for the first study raise questions about its generalisability. In that study, all patients 
had to demonstrate 12% or more reversibility to inhaled terbutaline and bronchodilator 
reversibility for the patients had a very high mean value of 24.5%. Selecting such a 
population has the potential to bias the population towards a group that is 
disproportionately responsive to all β2-agonists (i.e. to both short and long acting). Such a 
population may be less likely to demonstrate the pharmacogenetic effect under study for the 
analysis. In addition, it has been observed that mean FEV1 values are much higher (between 
90-97% of mean predicted) in asthmatic children attending clinics in Northern Europe
124-
126
. A post hoc analysis of a randomized controlled trial on adults with asthma shows that, 
relative to Gly/Gly patients with asthma, Arg16Arg patients may have an impaired 
therapeutic response to salmeterol, measured as improvement in lung function, either in the 
absence or the presence of inhaled corticosteroids
127, 128
. In the previous analysis (432 
participants with lung function data)
 21
, demonstration of an effect of Arg16 homozygous 
status on airway obstruction was not observed. In the current analysis on over twice the 
population size (n=879 with FEV1/FVC values), I have shown that, while FEV1/FVC is 
reduced overall in this population (mean 0.88), there is a small but significant reduction in 
FEV1/FVC in participants on higher steps of asthma treatment only in the Arg16Arg 
homozygous population of young asthmatics (0.88 versus 0.84; P=0.002) (figure 4.2.1). It 
117 
 
is doubtful whether such a small difference in forced expiration ratio has any clinical 
relevance. 
 
In addition, results from studies on adult patients with asthma
123
 cannot often be 
extrapolated to children and teenagers with the disease. Long-term cohort studies have 
shown that asthma in childhood differs markedly from asthma during adult life
129
. For 
example, early sensitisation to inhaled allergens constitutes a significant risk factor for 
asthma until the teenage years, but not for adult asthma
127, 130,131
. Other aspects of asthma, 
e.g. eosinophil response
130-132
 and effects of maternal smoking
133
, show major differences 
between children and adults with asthma. This suggests that the effects of polymorphic 
variations that are important from the pharmacogenetic perspective could be different 
between children and adults with asthma. The development of tolerance to the non-
bronchodilator (e.g. mast cell-mediated) actions of inhaled β2-agonists in patients with 
relatively mild asthma may also interact with these effects
134
. With the vast majority of my 
participants being aged <15 years (86%) and with the maximum age of participants being 
22 years, this study firmly focuses on children with this disease. I feel that the exploration 
of the role of ADRB2 genotype primarily in childhood complements the observations of 
other studies on adults, providing a more complete picture of the effects of this genotypic 
variation across asthmatics of different age-groups. 
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Chapter 3 
 
 Filaggrin Null Mutations Are Associated With Increased Asthma Exacerbations In 
Children And Young Adults 
 
Since completion of the data collection for the initial study
22
, recruitment of patients with 
asthma has continued for the Scottish cohort primarily ascertained with asthma to generate 
statistical power to investigate further the possible roles of filaggrin gene defects on asthma 
medication use
23
 and, subsequently, risk of asthma exacerbations
103
. The data demonstrate 
that individuals with FLG null alleles have a significantly increased risk of exacerbations 
requiring hospital admissions, courses of oral steroids, or experiencing school absences
103
. 
  
On sub-group analysis, the effect of FLG mutations on asthma exacerbations is significant 
only for participants with relatively mild asthma controlled on inhaled steroids, with 
inhaled salbutamol according to need. There is, however, a trend in the direction of greater 
morbidity in the presence of FLG mutations in participants on higher steps of asthma 
treatment (i.e. additional inhaled long-acting beta agonists with or without oral 
montelukast; Figure 4.3.4). This occurs against a background of an overall increasing 
prevalence of asthma exacerbations with greater asthma medication use (Figure 4.3.3). The 
overall prevalence of the FLG null alleles was higher in participants reporting asthma 
exacerbations in the previous six months in comparison to those that did not (46.0% versus 
34.5%), and this overall difference was significant (p= 0.01; Figure 4.3.2). 
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The individual contribution to the overall signal (exacerbations) of the 2282del4 allele was 
lower than that observed for the R501X mutation. In the previous study, a differential 
penetrance of these two mutations on the requirements for asthma medication was 
observed
23
, and other studies have seen a lower penetrance of the 2282del4 allele in asthma 
related phenotypes, but not eczema related phenotypes
135
. The mechanism of this is not 
known, but may be related to an as yet uncharacterised functional difference in individuals 
with the 2282del4 allele which has the potential to encode filaggrin repeats, which is 
definitely not the case for the R501X allele, which truncates the protein at the beginning of 
the first repeat. Interestingly a milder eczema phenotype has been reported for mutations 
that are much further towards the 3  end of the gene, although it has been difficult to detect 
any functional filaggrin in these individuals
73, 84
. Further work is required to delineate 
possible mechanistic differences in these alleles that may lead to different disease 
susceptibility. A significantly greater proportion of FLG null allele carriers with asthma 
were on higher BTS treatment steps 3 and 4 
23
. This work reinforces the position that 
epithelial barrier defects resulting from FLG mutations have an major influence on day-to-
day aspects of asthma management and control, including overall risk of asthma 
exacerbations
103
, use of oral steroids
103, together with ‗as required‘ doses of inhaled 
bronchodilators
23
 and regular asthma medication needs
23
. FLG gene status appears to 
influence the overall burden of disease in asthmatic children and young adults. An 
understanding of the possible relationship between filaggrin gene defects and asthma might 
unfold newer hypotheses that focused primary prevention strategies for asthma may be 
particularly cost effective and beneficial in specific genotype- stratified populations
27.
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Exacerbations cause the greatest concern to individuals with asthma and can be life- 
threatening. They also account for the largest proportions of health costs of asthma
136
. 
Exacerbations of asthma symptoms diminish the quality of life of the patients and their 
families
10, 13, 14
. Asthma exacerbations are triggered by several environmental factors 
including allergens, air pollutants
137
 and respiratory viral infections, rhinoviruses being the 
most frequent
138-140
. The mechanisms of viral induced asthma exacerbations are different 
from those with allergen exposure, possibly explaining the degree of refractoriness to 
inhaled or oral corticosteroids
141, 142
. The possible up-regulation of epithelia TH2-type 
immunity with preferential activation of the immunological cascade as a likely mechanism 
for the role of epidermal permeability on asthma medication needs has been discussed 
previously
23
. Similar mechanisms could explain the associations between filaggrin gene 
defects and the increased risk of asthma exacerbations in children and young adults 
reported here. However, asthma medication requirements do not necessarily reflect the risk 
of asthma exacerbations (Figure 4.3.3), while other forms of genetic variation that affect 
asthma exacerbation risk do not influence asthma medication requirements
24
 . Other 
mechanisms could contribute to the overall picture. Therefore, keratinocytes differentiated 
in the presence of IL-4 and IL-13 exhibit significantly reduced filaggrin gene expression, 
suggesting a regulatory role for the atopic immune response on the skin barrier defect
143
. It 
is possible that multiple mechanisms, including possible interactions between IL-13
30
 and 
filaggrin gene polymorphic variations, could be involved in mediating the observed 
associations between filaggrin gene defects and the overall burden of asthma (i.e., 
susceptibility
22
, medication requirements
23
 and risk of exacerbations
103
).  
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Chapter 4  
 
Epithelial Permeability Is Increased In Children With Filaggrin-Related Barrier 
Defects In Skin But Not In Gut 
 
I have observed that the permeability of the skin, as measured by transepidermal water loss, 
is around 50% higher in children heterozygous for filaggrin gene defects compared to 
clinically unaffected children but the permeability of the intestinal barrier, as measured by 
dual sugar absorption tests, is not different.  Moreover, while it was confirmed that 
filaggrin is expressed in human skin
22
, no evidence for expression was found in the nasal 
(inferior turbinate) mucosa or in the oesophagus (proximal, mid or distal) 
100
. 
 
A recent systematic review and meta-analysis has assessed the overall evidence to 
demonstrate that filaggrin gene defects increase the risk of developing allergic sensitisation, 
atopic eczema, and allergic rhinitis 
144, 145
. This aspect of my work aimed to explore the 
biological mechanisms underlying these observations. My work shows that skin but not gut 
permeability is impaired in children carrying a common genetic defect in the skin barrier 
protein, filaggrin.  
Alterations in gut epithelial permeability have been linked to immunologically mediated 
disease in children. IgE deposits have been demonstrated on cutaneous Langerhans and 
mast cells which may account for the cutaneous, intestinal and pulmonary signs observed in 
Henoch-Schönlein purpura
146
. It is postulated that stimulation of IgE-sensitized mast cells 
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by specific antigens in the presence of IgA circulating immune complexes may result in the 
release of vasoactive substances, increased capillary permeability and perivascular 
deposition of IgA
146
. In addition, the effects of probiotics have been attributed to 
normalisation of the increased intestinal permeability and balancing gut microecology, 
improvement of the immunological defence barrier (IgA) of the intestine, alleviation of the 
intestinal inflammatory response, and downregulation of proinflammatory cytokines 
characteristic of local and systemic allergic inflammation
147
.A similar mechanism might be 
responsible in development of the atopic diseases. There is need for an exploration of 
epithelial permeability in gut alongside skin, and the specific role of filaggrin, in various 
allergies in children, e.g. peanut allergy, cow‘s milk allergy, egg allergy and house dust 
mite allergy, to identify the routes of allergen entry (skin, respiratory tract or gastro-
intestinal tract), for atopic diseases like asthma and eczema in children. 
 
I have presented evidence that is consistent with a link between filaggrin gene defects and 
skin permeability. Since filaggrin increases the risk of eczema and asthma, it is inevitable 
that the disease profile of the filaggrin heterozygous children will be different from children 
who are representative of the general population. These differences could have secondary 
effects on skin permeability. For example, skin permeability may be increased in children 
with asthma and eczema as a result of latent skin inflammation irrespective of filaggrin 
gene status. Therefore, a much larger study, to define the effects of co-existing, potentially 
confounding morbidities such as eczema or asthma and the role of other genetic variations, 
may help establish a causal relationship between filaggrin gene defects, skin permeability 
and common allergen sensitisation. Such studies, although difficult to perform, will help 
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improve our understanding of the mechanisms underlying filaggrin-related allergen 
sensitisation, thus helping the development of intervention trials that aim to reduce the 
burden of filaggrin-related allergic diseases in children. 
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Chapter 5:  
 
Future Work 
 
 Designing a genotype-stratified randomised controlled trial at asthma 
management step 3 of the British Thoracic society guideline  
 
An important step in further testing the hypothesis that the study of genotypic variation 
could contribute to impaired management of children with asthma is through the design of 
implementation of prospective randomised controlled trials. I have worked with colleagues 
to design a randomised controlled trial to compare the efficacy of montelukast versus 
salmeterol as add-on to inhaled fluticasone in at-risk children with asthma possessing the 
homozygous arginine-16 β2-adrenoceptor genotype.   
 
In children with asthma managed on step 3 of BTS guidelines for asthma treatment or 
equivalent, salmeterol provides better asthma control than montelukast
18
.  However, in 
practice, the efficacy of salmeterol for improving asthma control in individual children is 
often variable
104
. Recently, the US Food and Drug Administration (FDA) have raised 
concerns regarding the efficacy and safety of long-term salmeterol use in children and 
adults with asthma
148-150
.  
 
We have identified of a step-wise increase in the risk of asthma attacks per copy of the 
Arg16 allele on the ADRB2, in asthmatic children on regular salmeterol
21, 104
. This led to 
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the hypothesis that children carrying this allele could be less responsive to salmeterol and 
may experience relatively better asthma control with montelukast. My observational data 
indicated that any such difference in efficacy could be more prominent in children who are 
homozygous, rather than heterozygous, for the Arg16 allele, as they carry the maximum 
‗gene dose‘104. If a significant difference in efficacy exists in practice, prior testing for the 
Arg16 allele may predict response and guide choice of ‗controller‘ therapy, thereby 
reducing the risk of treatment failure or deterioration with salmeterol in a proportion of 
these children, while improving its safety profile. As 1 in 7 in the population is 
homozygous for this allele
64, 117
, such predictability of response may improve the cost-
effectiveness of asthma therapy in children. 
 
The addition of anti-leukotrienes, or the substitution of long-acting inhaled β2-agonists with 
other medication, could alter the response. Receptor desensitization and down-regulation 
has been described with the chronic use of β agonists. This effect may not be the same with 
all beta-agonists and may be related to their stabilization of altered receptor states.  
 
As a follow-up to the research reported above, I am working with my colleagues to perform 
a proof-of-principle randomised controlled trial to test the hypothesis that genetically 
susceptible children who possess the   homozygous for the Arg16 allele might experience 
superior long-term asthma control with montelukast compared to salmeterol as add on to 
inhaled fluticasone. We have designed the study as follows. 
 The BREATHE database is used to identify children (5-18 years) homozygous for the 
Arg16 genotype variation for participation in this study. 62 children currently on regular 
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inhaled corticosteroids as preventer medication for asthma have been recruited. All 
participants had a history of at least one of the following within the previous 12 months as a 
result of asthma: school absences, course of oral steroids, out-of-hours visits to general 
practice or hospital admissions. 
   
Participants are randomly allocated to one of two treatments at the screening visit- 
Flixotide® (fluticasone propionate) via accuhaler (Diskus) dry powder inhaler device as per 
current inhaled steroid dose plus oral montelukast; or Seretide® (salmeterol plus equivalent 
dose of fluticasone) via accuhaler dry powder inhaler device as per current inhaled steroid 
dose plus placebo for montelukast.  The study is designed as a pragmatic randomised 
controlled trial. The trial is not blinded as the inhalers are not packaged in identical dry 
powder inhalers.  
 
Participants are randomly assigned to the two groups at baseline visit, by using concealed 
web-based randomisation process. At baseline visit, all participants undergo detailed 
clinical examination. Exhaled nitric oxide (Aerocrine, Solna, Sweden)
151
 and pulmonary 
function (forced expiratory volume at 1 second (FEV1), forced vital capacity (FVC), peak 
expiratory flow rate (PEFR), forced expiratory flow between 25% and 75% of vital 
capacity (FEF25%-75%)) (Micromed, Rochester, United Kingdom) are measured at baseline. 
Patients are provided with an asthma symptom diary to record controller and reliever 
medication use and exacerbation symptoms. Participants return every 3 months for diary 
review, medication compliance review, spirometry, exhaled nitric oxide testing and safety 
and efficacy assessments. A standard protocol is followed for spirometry
106
. Compliance is 
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monitored by viewing counters that calculated the number of actuations used from the 
accuhaler. The diary cards are used as a secondary compliance check.  
 
 School absence, prospectively measured as individual events over 1 year, constitutes the 
primary outcome measure.  Secondary outcome measures include asthma-related 
hospitalisations, requirement of courses of oral steroids, daily asthma symptoms as reported 
by the participants, quality of life as measured by the Juniper paediatric asthma quality of 
life questionnaire (PAQLQ)
 152,153
, nitric oxide levels and spirometry.  
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 A Proof-of-Concept Study to evaluate the benefit from ipratropium bromide 
versus salbutamol as reliever in children with asthma carrying the Arg16 
variation of β2-receptor genotype 
 
My work has shown that there is an increased risk of asthma attacks in a particular genetic 
configuration (Arg16 heterozygous and homozygous status on the β2-receptor gene) in 
children and young adults with asthma on frequent (once daily or more) as required doses 
of inhaled salbutamol, a common reliever medicine acting via β2-receptor
104
 . This effect 
was not observed in participants with asthma who are not exposed to inhaled β2-agonist on 
a daily basis. The interaction between genotype and daily use of any inhaled β2-agonists (as 
required salbutamol and/or salmeterol) had a significant effect on the risk of asthma 
exacerbations (p=0.022)
104
. As the participants on inhaled long-acting β2-agonists were also 
on short-acting β2-agonists, what proportion of the adverse effect of increased risk of 
exacerbations in the ‗real-life‘ scenario results through the use of long-acting, in 
comparison to the use of short-acting, β2-agonists could not be explored. However, this 
question may be resolved through a study that involves the randomization of asthmatic 
children carrying the Arg16 allele to comparator arms of ‗reliever‘ medication, short-acting 
β2-agonist versus ipratropium bromide (an anticholinergic agent which decreases bronchial 
smooth muscle contractility and does not act via the β2 receptor), with risk of asthma 
exacerbations as the primary outcome measure. 
 
There was an increase in the risk of school absences and requirement for courses of oral 
steroids due to exacerbations over a 6-month period of reporting, in addition to the overall 
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effect on asthma exacerbations
104
. However, there was no significant effect of genotype and 
short-acting β2-agonist use on the risk of hospital admissions. School absences, requirement 
of oral steroids and hospital admissions due to asthma, represent different aspects of asthma 
exacerbations that have different effects on children and young adults in the community. 
School absences have an effect on children‘s education, and oral steroid courses represent 
the use of primary care resources, whereas hospital admissions represent the effect on 
secondary care services. Therefore my findings appear to have a greater relevance for the 
burden of asthma in the community and primary care than hospital settings. 
 
My primary hypothesis for the proposed study is that children with asthma, carrying the 
Arg16 variation of the β2-receptor genotype experience better asthma control including a 
lower risk of exacerbations over 1 year if maintained on reliever therapy with inhaled 
ipratropium bromide compared to salbutamol. The secondary hypothesis is that there is an 
improvement in asthma specific quality-of-life in children with asthma, carrying the Arg16 
variation of the β2-receptor genotype on inhaled ipratropium in comparison to inhaled 
salbutamol over a period of 1 year.  
 
I would like to perform a randomized controlled trial (parallel design) of inhaled 
ipratropium versus inhaled salbutamol as reliever on asthmatic children treated with inhaled 
steroids, with a history of any measure for exacerbations over the past year, using asthma 
exacerbations over a period of 1 year as the primary outcome.  
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Children with and without the Arg16 allele will be recruited from the genotyped population 
of asthmatic children. The primary hypothesis to be tested is that inhaled ipratropium is 
associated with reduced school absence in comparison to inhaled salbutamol during 
exacerbation over a period of 1 year in asthmatic children with Arg16 allele. 
 
The secondary outcome measures for the proposed study is that inhaled ipratropium is 
associated with reduced overall asthma exacerbations and improved asthma specific 
quality-of-life during exacerbation in comparison to inhaled salbutamol over a period of 
one year. 
 
This study is important in the context of personalization of treatments according to 
genotype, which may represent a new therapeutic strategy for children with a common 
disease. My work intends to help target reliever therapy to make treatment more effective, 
thereby reducing the burden of childhood asthma. School absences have an effect on 
children‘s education, and oral steroid courses represent the use of primary care resources. 
Therefore this study will have a greater relevance for the burden of the disease in the 
community and primary care.  
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SECTION VII 
 
CONCLUSION 
 
I have explored the associations of two common genotypes with increased risk of 
exacerbations in children with asthma. I have also shown that the most commonly used 
broncho-dilator may in the long term worsen asthma exacerbations in a susceptible group 
of children with asthma. Further exploration of the pathway(s) via which these gene 
variations affect the disease outcome may lead to a clearer understanding of these effects 
and help the introduction of genotype-specific treatment of a common chronic disease. 
Reduction in the disease burden of childhood asthma can therefore be achieved by targeting 
the therapy according to the genotype variations. 
 
The identification of a gene and subsequently its disease associations may eventually lead 
to genotype-directed treatment. This process includes replication of earlier findings, 
functional studies to identify mechanisms of the gene action and, finally, intervention 
studies. Significant progress has been made in the identification of asthma susceptibility 
genes. Further research is required for replication and characterization of the gene function. 
This may enable us to realize benefits to patient treatment that studies of the genetic basis 
of asthma have the potential to deliver. 
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 Further exploration of the gene mechanisms influencing disease outcomes  
β2-adrenergic receptors are activated by β2-agonists such as salbutamol or salmeterol. This 
leads to the activation of the cascade of events by targeting β2-adrenergic receptors. 
Signalling through β2-adrenergic receptors mediates direct relaxation of airway smooth 
muscle and consequent broncho-dilation pathways. Stimulation of β2-adrenergic receptors 
on inflammatory cells like mast cells, eosinophils, neutrophils and lymphocytes, activates a 
signalling cascade that inhibits the release of inflammatory mediators and cytokines
154
.  
Therefore, it is an important prerequisite to understand these pathways, which will assist in 
defining the variability in therapeutic responses for β2-agonists
155
. Owing to the complex 
therapeutic response of the β2-agonists, a broader genomics approach will help in targeting 
asthma therapy for the susceptible patients. This could be achieved by focusing either on 
the receptors at which the drug binds directly, signal transduction cascades, or downstream 
proteins and proteins involved in the relaxation of the airway smooth muscle.  
 
Filaggrin protein has not been isolated from the respiratory tract
100
. Yet asthmatic children 
with FLG null mutations are at increased risk of asthma exacerbations
105
. Therefore 
functional studies are essential to define the underlying mechanism for the association of 
asthma exacerbations with FLG null mutations. Replication studies of the previously 
reported association of the FLG mutations R501X and 2282del4 with atopic eczema and 
eczema-associated asthma show that these mutations predispose equally to the atopic and 
nonatopic forms of eczema, suggesting that the onset of eczema may occur independently 
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of allergic sensitization. It has also been demonstrated in a population-based cohort that the 
defect in a single gene may predispose to different allergic phenotypes of the atopic march 
and that the expression of the subsequent disease stages requires the presence of eczema
156
. 
These findings highlight the role of the epidermal barrier in the pathogenesis of allergic 
sensitization and allergic disease and also stress the importance of maintaining or repairing 
the epidermal barrier in infantile eczema as a possible means of preventing allergic airways 
disease.  
 
 How to reduce the disease burden of childhood asthma 
 
Exacerbations not only affect patients‘ quality of life, it also account for the largest 
proportions of health costs of asthma
136
. 43% of children reported to have been prevented 
from doing everyday activities due to their asthma
157
. The estimated cost of treating a child 
with asthma (£181) is higher than the cost per adult with asthma (£162)
157
. Asthma costs 
the UK approximately £2,237 million per year
16
, and the US approximately $37.2 billion 
per year
158
. In the UK lost productivity accounts for the direct costs to the NHS of around 
£889 million and £161 million in benefits
159
. Difficult to control asthma costs the NHS 
£680 million a year
15
 and emergency hospital admissions for asthma cost the NHS more 
than £45.8 million a year
15
.  Asthma care costs a primary care trust over £4.25 million a 
year
160
.  
 
Even a relatively small reduction in the emergency visits to general physicians through 
such genotype-targeted reliever therapy might not only be cost-effective, but also 
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significantly improve the quality of life of the children. However, introducing 
pharmacogenetics into the clinical practice can be quite complex. There is always a context 
to a pharmacogenetic test when it enters a clinical situation
161
. The contextual approach 
starts from the clinical experience, looking at the ethical aspects of pharmacogenetics as 
seen by the people beginning to use this new technology. There is a substantial role of 
clinicians‘ ‗resistance‘ to various aspects of pharmacogenetics161, with resistance being a 
political term referring to ‗elements of discourse that seem to conflict with or evade more 
dominant assumptions and priorities‘162. 
 
Prescribing policies get set by healthcare providers and funders, and if there were definitive 
tests that would predict response on a genetic basis, there might be a pressure from the 
health authority and government level to focus prescribing
161
. Such decisions, made at the 
population level need not necessarily be in harmony with the wishes and needs of the 
individual, or people closely related to that individual
161
. In this sense, the needs of the 
individual patient are in conflict with those of society at large.  
 
 
 Exploring the context of a genotype-directed management in current clinical 
practice: The example of Herceptin 
 
Herceptin, the pharmacogenetic product currently being prescribed by clinicians for breast 
cancer in patients with HER2 gene variations, is in many ways subject to bureaucratic 
pressures
161
. These go beyond the issues involved in any normal expensive treatment; the 
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point about pharmacogenetics being that a test will be required for the drug to be prescribed 
properly. Yet there are several levels at which Herceptin is controlled and limited, largely 
on economic grounds. Herceptin was developed with the intention of being prescribed to a 
genetically identified sub-group of patients. As the first pharmacogenetic drug licensed in 
the US (in 1998) and the UK (a year later), Herceptin is often cited as a pharmacogenetic 
success story, although such a claim rather glosses over the number of times the drug was 
almost cancelled during development
163
.  
 
There may be important ethical problems with pharmacogenetics, but they may be 
overridden by the benefits like potential gains from pharmacogenomics, in terms of both 
patient well-being and cost of healthcare, and heavily outweigh the risks
164
. Requirements 
for confidentiality and limitation of using the genetic data place major constraints on the 
ability to use the genetic information in modifying the disease outcomes. Therefore the 
need for education, information, and teaching about genetics is large and evident, to put 
risks in perspective and illuminate the potential benefits
165
. One obvious ethical result of 
the benefits brought by pharmacogenetics is that one day ‗it may be considered unethical 
not to carry out such tests routinely to avoid exposing individuals to doses of drugs that 
could be harmful to them‘166. Hence testing the genotype of asthmatic children to avoid 
exposure to β2agonist in susceptible population will be an important step forward in treating 
childhood asthma.   
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 Pharmacogenetics in childhood asthma 
 
The new US and EU regulations on medicines emphasize the need for the  
pharmacogenetic approach
167
. Although the pathophysiology of childhood and adult  
asthma may share the same underlying mechanisms, effects on growth and  
development, and the adverse effects of asthma treatments differ between children  
and adults 
129,168
. There is a need for successful paediatric clinical trials  
safeguarding the participants as well as focusing on the outcome measures relevant to  
the paediatric population
169-171
. 
 
While there is considerable literature related to the genetic testing of children, both  
for childhood and later onset adult conditions
172
, there has been very little discussion 
of the ethics of pharmacogenetic research on children. What work there has been in 
 this area highlights the complex issues around informed consent to such trials (from  
both children and their parents), the limitations on risks that can be taken with 
 children, and the complicated genetics involved in those cases where genes are 
 expressed differently in children compared to adults
173
.   
  
One obvious clarification concerns the nature of the gene being tested for, and  
whether there is any ‗overlap‘ between a gene‘s role in the pharmacogenetics of a  
particular drug, and disease prediction or prognosis. This ‗ancillary information‘ in  
pharmacogenetic testing may be more common than is often assumed
174
 and there are  
some examples where the ethically contentious nature of this additional information  
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has inhibited the clinical uptake of pharmacogenetic tests
175
.  
 
 Ethical issues  
 
Pharmacogenomic approach is not without its challenges, not the least of which is the 
ethics questions surrounding the privacy of genetics data
176
. It may not necessarily be the 
case that a clear line can be drawn between a pharmacogenetic test and a test for disease 
susceptibility as genotypes relevant to drug response may overlap with disease 
susceptibility, and divulging such information could jeopardise an individual
177
. Genotypes 
related to drug metabolism or mechanisms are often related to the diseases
178
. 
 
Although the ethical debates around pharmacogenetics are largely being set by scientific 
and commercial considerations
179
, the bioethicists have also explored potential problems 
that may arise with pharmacogenetics
180-182
. The emphasis on the ethical issues involved in 
pharmacogenetic research, debates surrounding informed consent. In the case of 
pharmacogenetics, the worries are that patients may not understand the reason their DNA is 
being sampled, or that the imprecise nature of much pharmacogenetic research means that, 
by definition, it is not possible to give patients full information about the uses to which 
their DNA may be put. Related to this is the concern that their genetic data may ‗leak‘ into 
the broader community due to inadequate confidentiality and may thus lead to social or 
financial stigmatisation
183
. Although it is ensured that the patients‘ DNA, personal, and 
medical data are encoded to prevent any infringement of privacy, ‗full anonymisation‘ (i.e. 
the removal of all identifiers, making tracing the patient all but impossible) might prevent 
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us feeding back results to patients. There are also the potential problems which may arise 
from the clinical application of pharmacogenetics. Although there are major personal 
implications of clinical pharmacogenetics, such as the impact on insurance
184, 185
, there 
could be broader, systemic issues that will arise, such as physician (and pharmacist) 
education, the direct marketing of pharmacogenetic tests to the public, and possible issues 
of legal liability
186-188
. 
 
Therefore obtaining informed consent within the context of pharmacogenetic testing and its 
application in management of childhood asthma is of immense importance. Respecting 
patients‘ autonomy in making decisions over treatment, and getting their ‗informed 
consent‘, is at the core of modern medical ethics. Both in terms of the rules laid down for 
ethical clinical practice
189, 190
 and in philosophically based medical ethics
191
, the need to get 
informed consent from patients is crucial. Yet a considerable amount of empirical research 
suggests just how hard it is to decide exactly what counts as ‗informed‘ consent192. Prior 
implementation of the pharmacogenetic testing in routine practice to treat such a common 
childhood disease, there is a need to conduct genotype-specified clinical trials in children to 
answer specific questions of clinical importance.  
 
 Parental views on pharmacogenetics and genotype-specific clinical trials in 
children  
 
In general, parents felt motivated to consent their children entering pharmacogenetic  
clinical trials because there was a possible perceived benefit for their own child found  
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to carry the genotype, but also the satisfaction of knowing they may be helping other  
children with asthma in the future. The participants and their parents were interested  
in contributing to the understanding of the gene-environment interactions in  
childhood asthma and allergy.  Most parents welcomed being contacted with follow- 
up genetic information leading to further studies that could help the management of  
specific issues that concerned their child. 
 
The current devolution of budgets within healthcare providers can cause problems not in 
funding for the drug, but the funding for the genetic testing, which is not routinely done. It 
is of course ironic that in this case there is enough money for the relatively expensive 
treatment, but no budget for the test.  Using various measurement tools for quantifying risk, 
various forms of genetic variation, such as for the β2 adrenergic receptor gene, have been 
shown to influence the likelihood of asthma exacerbations, possibly through an interaction 
with pharmacological treatments
21,29,30
. I predict that the study of genetic variation in 
relation to clinical outcomes in asthma will further explain underlying mechanisms for this 
disease, identify at-risk populations for susceptibility, severity and major life-events, define 
drug choice, and contribute overall to significantly improved management strategies for 
asthma in the future and will also have a major implication in cost-reduction for the 
National Health Service. I hope this also provides a platform for further discussion on the 
methodology of prospective genotype-stratified trials in children; as such trials are likely to 
become more relevant to the progress in pharmacogenetic therapeutics in the future.
140 
 
SECTION VIII 
 
REFERENCES 
 
1. Deen JL, Vos T, Huttly SR, Tulloch J. Injuries and noncommunicable diseases: 
emerging health problems of children in developing countries. Bulletin of World Health 
Organisation. 1999; 77 (6):518-24. 
2. Fuhlbrigge AL, Adams RJ, Guilbert TW, Grant E, Lozano P, Janson SL, et al. The 
burden of asthma in the United States: level and distribution are dependent on interpretation 
of the national asthma education and prevention program guidelines. Am J Respir Crit Care 
Med. 2002 Oct 15; 166 (8):1044-9. 
3. World Health Organization Fact Sheet Fact sheet No 307: Asthma (2009) 
http://www.who.int/mediacentre/factsheets/fs307/en/print.html, Accessed 08-05-10  
4. Fanta CH (March 2009). "Asthma". N. Engl. J. Med. 360 (10): 1002–14. 
5. Luskin AT. What the asthma end points we know and love do and do not tell us. J 
Allergy Clin Immunol 2005 Apr; 115(4 Suppl):S539-45. 
6. Moorman JE, Rudd RA, Johnson CA, King M, Minor P, Bailey C, et al. National 
surveillance for asthma--United States, 1980-2004. MMWR Surveill Summ. 2007 Oct 19; 
56 (8):1-54. 
7. National Asthma Campaign. Starting as we mean to go on. An audit of  
children‘s asthma in the UK. Asthma 2002; J8 (Special supplement). 
8. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive 
summary of the GINA Dissemination Committee report. Allergy 2004 May;59(5):469-78. 
141 
 
9. Simpson CR, Sheikh A (2010). "Trends in the epidemiology of asthma in England: a 
national study of 333,294 patients". J R Soc Med 103 (3): 98–106. 
10. Andersson F, Borg S, Stahl E. The impact of exacerbations on the asthmatic patient‘s 
preference scores. . J Asthma. 2003;5:615-23. 
11. Ober C, Tan Z, Sun Y, Possick JD, Pan L, Nicolae R, et al. Effect of variation in 
CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med. 2008 
Apr 17;358(16):1682-91. 
12. Bai TR, Knight DA. Structural changes in the airways of asthma: observations and 
consequences . Clinical Science. 2005;108:463-77. 
13. Lane S, Molina J, Plusa T. An international observational prospective study to 
determine the cost of asthma exacerbations (COAX). . Respir Med. 2006;100:434-50. 
14. Skrepnek GH, Skrepnek SV. Epidemiology, clinical and economic burden, and natural 
history of chronic obstructive pulmonary disease and asthma. Am J Manag Care. 2004;10(5 
Suppl):S129-38. 
15. Living on a knife edge. Asthma UK 2004. 
16. www.asthma.org.uk/news_media/media_resources. National Asthma Campaign. Last 
accessed October 2009 
17. Milton B, Whitehead M, Holland P, Hamilton V. The social and economic 
consequences of childhood asthma across the lifecourse: a systematic review. Child Care 
Health Dev. 2004 Nov;30(6):711-28. 
18. British Guideline on the Management of Asthma. British Thoracic Society Scottish 
Intercollegiate Guidelines Network. Thorax. 2008 May;63(Suppl 4):iv1-121. 
142 
 
19. Dawson KP, Jandera E, Penna AC. The prehospital management of children with acute 
asthma. Journal of Paediatrics and Child Health. 1992 Aug; 28(4): 321-2. 
20. Flores G, Abreu M, Tomany-Korman S, Meurer J. Keeping Children With Asthma Out 
of Hospitals: Parents' and Physicians' Perspectives on How Pediatric Asthma 
Hospitalizations Can Be Prevented Pediatrics. 2005 October;116(4):957-65. 
21. Palmer CNA, Lipworth BJ, Lee S, Ismail T, Macgregor DF, Mukhopadhyay S. 
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics 
taking regular salmeterol. Thorax. 2006 Nov;61(11):940-4. 
22. Palmer CNA, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. 
Common loss-of-function variants of the epidermal barrier protein filaggrin are a major 
predisposing factor for atopic dermatitis. Nature Genetics. 2006;38:441-6. 
23. Palmer CNA, Ismail T, Lee S, Terron- Kwiatkowski A, Zhao Y, Liao H, et al. Filaggrin 
null mutations are associated with increased asthma severity in children and young adults. 
Journal of Allergy and Clinical Immunology. 2007 Jul;120(1):64-8. 
24. Palmer CNA, Doney AS, Ismail T, Lee SP, Murrie I, Macgregor DF, et al. PPARG 
locus haplotype variation and exacerbations in asthma. Clin Pharmacol Ther. 2007 May; 
81(5):13-8. 
25. Palmer CNA, Doney AS, Lee SP, Murrie I, Ismail T, Macgregor DF, et al. Glutathione-
S-transferase M1 and P1 genotype, passive smoking and peak expiratory flow in asthma. 
Pediatrics. 2006;118:710-6. 
26. Tavendale R, Macgregor DF, Mukhopadhyay S, Palmer CN. A polymorphism 
controlling ORMDL3 expression is associated with asthma that is poorly controlled by 
current medications. J Allergy Clin Immunol. 2008 Apr;121(4):860-3. 
143 
 
27. Arshad SH. Primary prevention of asthma and allergy Journal of Allergy and Clinical 
Immunology. 2005 July;116(1):3-14. 
28. Husain A, Loehle JA, Hein DW. Clinical pharmacogenetics in pediatric patients. 
Pharmacogenomics. 2007 Oct;8(10):1403-11. 
29. Elbahlawan L, Binaei S, Christensen ML, Zhang Q, Quasney MW, Dahmer MK. 
Beta2-adrenergic receptor polymorphisms in African American children with status 
asthmaticus. Pediatr Crit Care Med. 2006 Jan;7(1):15-8. 
30. Weir TD, Mallek N, Sandford AJ, Bai TR, Awadh N, Fitzgerald JM, et al. Beta2-
Adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. Am J Respir 
Crit Care Med. 1998 Sep;158(3):787-91. 
31. Green S, Turki J, Innis M, Liggett S. Amino-terminal polymorphisms of the human beta 
2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 
1994 Aug 16;33(32):9414-9. 
32. Cohen S, Taitz J, Jaffé A. Paediatric prescribing of asthma drugs in the UK: are we 
sticking to the guideline? Arch Dis Child. 2007 Oct;92(10):847-9. 
33. Thomas M, Turner S, Leather D, Price D. High-dose inhaled corticosteroid use in 
childhood asthma: an observational study of GP prescribing. Br J Gen Pract. 2006 
Oct;56(531):788-90. 
34. McCowan C, Hoskins G, Neville RG. Clinical symptoms and 'off-label' prescribing in 
children with asthma. Br J Gen Pract 2007 Mar;57(536):220-2. 
35. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global 
strategy for asthma management and prevention: GINA executive summary. European 
Respiratory Journal. 2008 Jan;31(1):143-78. 
144 
 
36. Fanta CH, Rossing TH, McFadden ERJ. Treatment of acute asthma: Is  
combination therapy with sympathomimetics and methylxanthines indicated? Am. J. Med 
1986;80:5-10. 
37. Nelson HS. Beta-adrenergic bronchodilators. N Engl J Med. 1995;333(8): 499-506. 
38. Sylvester JT. The tone of pulmonary smooth muscle: ROK and Rho music?  
Am. J. Physiol. Lung Cell Mol. Physiol. 2004;287:L624-630. 
39. Kume H, Hall IP, Washabau RJ, et a. βadrenergic agonists regulate KCa  
channels in airway smooth muscle by cAMP-dependent and independent mechanisms. 
J.Clin. Invest. 1994;93:371-379. 
40. Koike K, Yamashita Y, Horinouchi T, Yamaki F, Tanak Y. cAMP-independent 
mechanism is significantly involved in b2-adrenoceptor mediated tracheal relaxation. Eur. 
J. Pharmacol. 2004;492:65-70. 
41. Ostrom RS, Ehlert FJ. M2 muscarinic receptors inhibit forskolin- but not  
isoproterenol-mediated relaxation in bovine tracheal smooth muscle. J. Pharmacol. 
Exp.Ther. 1998;287:234-242. 
42. Chong LK, Peachell PT. β-Adrenoceptor reserve in human lung: A comparison between 
airway smooth muscle and mast cells. Eur. J. Pharmacol. 1999;378:115-122. 
43. Johnson M, Coleman RA, Sanjar S, Vardey CJ, Whelan CJ, Jenkins MM.  
Inhibition of natural anti-inflammatory mechanism by beta 2-agonists. Lancet 
1991;337(8747):982. 
44. Jackson CM, Lipworth B. Benefit-risk assessment of long-acting beta2- 
agonists in asthma. Drug Safety 2004;27(4):243-70. 
145 
 
45. Alving K, Weitzberg E, Lundberg J. Increased amount of nitric oxide in exhaled air of 
asthmatics. Eur Respir J. 1993 Oct;6(9):1368-70. 
46. Schleimer RP. Glucocorticosteroids: Their mechanisms of action and use in  
allergic diseases. In: Middleton EJ, Ellis EF, Yunginger JW, et al, eds. Allergy: Principles 
and Practice. 5th ed. St. Louis: Mosby, 1998: 638-660. 
47. Dahlén SE, Hedqvist P, Hammarström S, Samuelsson B. Leukotrienes are potent 
constrictors of human bronchi. Nature 1980;288(5790):484-6. 
48. Buckner CK, Krell RD, Laravuso RB, Coursin DB, Bernstein PR, Will JA.  
Pharmacological evidence that human intralobar airways do not contain different receptors 
that mediate contractions to leukotriene C4 and leukotriene D4. J Pharmacol Exp Ther. 
1986;237(2):558-62. 
49. Lynch KR, O'Neill GP, Liu Q, et al. Characterization of the human cysteinyl  
leukotriene CysLT1 receptor. Nature 1999 399(6738):789-93. 
50. Krell RD, Aharony D, Buckner CK, et al. The preclinical pharmacology of ICI 204,219. 
A peptide leukotriene antagonist. Am Rev Respir Dis 1990;141(4 Pt 1):978-87. 
51. Jones TR, Labelle M, Belley M, et al. Pharmacology of montelukast sodium  
(Singulair), a potent and selective leukotriene D4 receptor antagonist. Can J Physiol 
Pharmacol. 1995;73(2):191-201. 
52. Hay DW, Torphy TJ, Undem BJ. Cysteinyl leukotrienes in asthma: old  
mediators up to new tricks. Trends Pharmacol Sci. 1995 16(9):304-9. 
53. Cookson WO, Sharp PA, Faux JA, Hopkin JM. Linkage between immunoglobulinE 
responses underlying asthma and rhinitis and chromosome 11q. Lancet 1989; 1:1292–1295. 
146 
 
54. Swarra DT, Hakonarsonb H. Unraveling the complex genetic underpinnings of asthma 
and allergic disorders. Current Opinion in Allergy and Clinical Immunology 2010; 10 
55. Hawkins GA, Weiss ST, Bleecker ER. Clinical consequences of ADRbeta2 
polymorphisms. Pharmacogenomics 2008; 9:349–358. 
56. Moore PE, Ryckman KK, Williams SM, et al. Genetic variants of GSNOR and ADRB2 
influence response to albuterol in African-American children with severe asthma. Pediatr 
Pulmonol 2009; 44:649–654. 
57. Kobilka BK, Dickson RAF, Frielle T, Dohlman HG, Bolanowski MA, Sigal IS, et al. 
cDNA for the human P2-adrenergic receptor: a protein with multiple membrane spanning 
domains and encoded by a gene whose chromosomal location is shared with that of the 
receptor for platelet-derived growth factor. Proc Natl Acad Sci USA 1987;84: 46-50. 
58. Kobilka BK, Frielle T, Dohlman HG, Bolanowski MA, Dixon RA, Keller P, et al. 
Delineation of the intronless nature of the genes for the human and hamster 02-adrenergic 
receptor and their putative promoter regions. J' Biol Chem 1987; 262: 7321-7. 
59. Sheppard JR, Wehner JM, McSwigan JD, Shows TB. Chromosomal assignment of the 
gene for the human B2-adrenergic receptor. Proc Natl Acad Sci USA 1983; 80:233-6. 
60. Israel E, Drazen J, Liggett S, Boushey H, Cherniack R, Chinchilli V, et al. The effect of 
polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of 
albuterol in asthma. Am J Respir Crit Care Med. 2000 Jul;162(1):75-80. 
61. Taylor D, Drazen J, Herbison G, Yandava C, Hancox R, Town G. Asthma 
exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor 
polymorphism. Thorax. 2000 Sep;55(9):762-7. 
147 
 
62. Nelson H, Weiss S, Bleecker E, Yancey S, Dorinsky P. The Salmeterol Multicenter 
Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual 
pharmacotherapy plus salmeterol. Chest. 2006 Jan;129(1):15-26. 
63. Currie GP, Lee DK, Lipworth BJ. Long-acting beta2-agonists in asthma: not so 
SMART? Drug Saf. 2006;29(8):647-56. 
64. Drysdale C, McGraw D, Stack C, Stephens J, Judson R, Nandabalan K, et al. Complex 
promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression 
and predict in vivo responsiveness. Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10483-
8. 
65. Israel E, Chinchilli V, Ford J, Boushey H, Cherniack R, Craig T, et al. Use of regularly 
scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-
controlled cross-over trial. Lancet. 2004 Oct 23-29; 364(9444):1505-12. 
66. Wang WC, Mihlbachler KA, Brunnett AC, Liggett SB. Targeted transgenesis reveals 
discrete attenuator functions of GRK and PKA in airway beta2-adrenergic receptor 
physiologic signalling. Proc Natl Acad Sci U S A. 2009; 106 (35):15007-12. 
67. McGraw DW, Liggett SB. Heterogeneity in beta-adrenergic receptor kinase  
expression in the lung accounts for cell-specific desensitization of the beta2- 
adrenergic receptor. J Biol Chem. 1997; 272(11):7338-44. 
68. Jindal SK, Gupta D, Aggarwal AN, Agarwal R. Guidelines for Management of Asthma 
at Primary and Secondary Levels of Health Care in India (2005) [A Consensus Statement 
Developed under the World Health Organization and Government of India Collaborative 
Programme (2004-2005)]. Indian J Chest Dis Allied Sci. 2005;47:309-43. 
148 
 
69. National Institutes of Health NH, Lung, and Blood Institute. . Global Strategy for 
Asthma Management and Prevention. . Revised 2002 Cited on 1-29-03. 
70. Rachelefsky GS, Shapiro GG, Bergman D, Blessing-Moore J. Pediatric asthma: 
promoting best practice. Guide for Managing Asthma in Children. Rochester, N.Y.: 
American Academy of Allergy, Asthma and Immunology. 1999. 
71. Hancox RJ, Sears MR, Taylor DR. Polymorphism of the beta2-adrenoceptor and the 
response to long-term beta2-agonist therapy in asthma. European Respiratory Journal. 1998 
Mar;11(3):589-93. 
 72. Candi E, Schmidt R, Melino G. The cornified envelope: A model of cell death in the 
skin. Nature Reviews Molecular Cell Biology 2005 Apr; 6(4):328-40. 
73. Sandilands A, Terron-Kwiatkowski A, Hull PR, O'Regan GM, Clayton TH, Watson 
RM, et al. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and 
rare mutations in ichthyosis vulgaris and atopic eczema. Nat Genet. 2007;39(5):650-4. 
74. Hudson TJ. Skin barrier function and allergic risk. Nat Genet. 2006 Apr;38(4):399-400. 
75. Bisgaard H, Simpson A, Palmer CNA, Bønnelykke K, Mclean I, Mukhopadhyay S, et 
al. Gene-Environment Interaction in the Onset of Eczema in Infancy: Filaggrin Loss-of-
Function Mutations Enhanced by Neonatal Cat Exposure. PLoS Medicine. 2008;5:934-40. 
76. Smith F, Irvine A, Terron-Kwiatkowski A, Sandilands A, Campbell L, Zhao Y, et al. 
Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nature 
Genetics. 2006;38:337-42. 
77. Marenholz I, Nickel R, Rüschendorf F, Schulz F, Esparza-Gordillo J, Kerscher T, et al. 
Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march 
Journal of Allergy and Clinical Immunology 2006 October;118(4):866-71. 
149 
 
78. Barker JNWN, Palmer CNA, Zhao Y, Liao H, Hull PR, Lee SP, et al. Null Mutations in 
the Filaggrin Gene (FLG) Determine Major Susceptibility to Early-Onset Atopic Dermatitis 
that Persists into Adulthood. Journal of Investigative Dermatology. 2007;127:564-7. 
79. Morar N, Cookson W, Harper JI, Moffatt MF. Filaggrin mutations in children with 
severe atopic dermatitis. J Invest Dermatol. 2007 Feb 15. 
80. Ruether A, Stoll M, Schwarz T, Schreiber S, Fölster-Holst R. Filaggrin loss-of-function 
variant contributes to atopic dermatitis risk in the population of Northern Germany. British 
Journal of Dermatology. 2006 November; 155(5): 1093-4. 
81. Stemmler S, Parwez Q, Petrasch-Parwez E, Epplen J, Hoffjan S. Two common loss-of-
function mutations within the filaggrin gene predispose for early onset of atopic dermatitis. 
J Invest Dermatol. 2006;127:722-4. 
82. Weidinger S, Illig T, Baurecht H, Irvine A, Rodriguez E, Diaz-Lacava A, et al. Loss-of-
function variations within the filaggrin gene predispose for atopic dermatitis with allergic 
sensitizations Journal of Allergy and Clinical Immunology 2006 July;118(1):214-9. 
83. Nomura T, Sandilands A, Akiyama M, Liao H, Evans A, Sakai K, et al. Unique 
mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic 
dermatitis. J Allergy Clin Immunol. 2007 Feb; 119 (2):434-40. 
84. Sandilands A, Smith FJ, Irvine AD, McLean WH. Filaggrin's fuller figure: a glimpse 
into the genetic architecture of atopic dermatitis. J Invest Dermatol. 2007 Jun; 127(6):1282-
4. 
85. Lynley AM, Dale BA. The characterization of human epidermal filaggrin. A histidine-
rich, keratin filament-aggregating protein. . Biochim Biophys Acta. 1983;744:28-35. 
150 
 
86. Henderson J, Northstone K, Lee SP, Liao H, Zhao Y, Pembrey M, et al. The burden of 
disease associated with filaggrin mutations: a population-based, longitudinal birth cohort 
study. J Allergy Clin Immunol. 2008;121:872-7 e9. 
87. Ying S, Meng Q, Corrigan CJ, Lee TH. Lack of filaggrin expression in the human 
bronchial mucosa. J Allergy Clin Immunol 2006; 118:1386–1388. 
88. Hudson TJ. Skin barrier function and allergic risk. Nat Genet 2006; 38:399–400. 
89. Irvine AD, McLean WHI (2006) Breaking the (un) sound barrier: filaggrin is a major 
gene for atopic dermatitis. J Invest Dermatol 126:1200–2 
90. Rawlings AV, Harding CR (2004) Moisturization and skin barrier function. Dermatol 
Ther 17:43–8 
91. Aalto-Korte K (1995) Improvement of skin barrier function during treatment of atopic 
dermatitis. J Am Acad Dermatol 33:969–72   
92. Chamlin SL, Kao J, Frieden IJ, Sheu MY, Fowler AJ, Fluhr JW et al. (2002) Ceramide-
dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier 
function provide a sensitive indicator of disease activity. J Am Acad Dermatol 47:198–208 
93. Hata M, Tokura Y, Takigawa M, Sato M, Shioya Y, Fujikura Y et al. (2002) 
Assessment of epidermal barrier function by photoacoustic spectrometryin relation to its 
importance in the pathogenesis of atopic dermatitis. Lab Invest 82:1451–61 
94. Holm EA, Wulf HC, Thomassen L, Jemec GB (2006) Instrumental assessment of atopic 
eczema: validation of transepidermal water loss, stratum corneum hydration, erythema, 
scaling, and edema. J Am Acad Dermatol 55:772–80 
151 
 
95. Tomita Y, Akiyama M, Shimizu H (2005) Stratum corneum hydration and flexibility 
are useful parameters to indicate clinical severity of congenital ichthyosis. Exp Dermatol 
14:619–24 
96. Leung DY (2000) Atopic dermatitis: new insights and opportunities for therapeutic 
intervention. J Allergy Clin Immunol 105:860–76 
97. Oestmann E, Lavrijsen A, Hermans J, Ponec M. Skin barrier function in healthy 
volunteers as assessed by transepidermal water loss and vascular response to hexyl 
nicotinate: intra- and interindividual variability. Br J Dermatol 1993;128:130–136. 
98. Levin J, Maibach H. The correlation between transepidermal water loss and 
percutaneous absorption: an overview. J Control Release 2005;103:291–299. 
99. Seidenari S, Giusti G. Objective assessment of the skin of children affected by atopic 
dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved 
skin. Acta Derm Venereol 1995;75:429–433. 
100. De Benedetto A, Qualia CM, Baroody FM, Beck LA. Filaggrin expression in oral, 
nasal, and esophageal mucosa. Journal of Investigative Dermatology. 2008;128:1594-7. 
101. Rickham PP. Human experimentation. Code of ethics of the world medical 
association. Declaration of Helsinki. Br Med J 1964;2(5402):177. 
102. Rits IA. Declaration of Helsinki. Recommendations guiding doctors in clinical 
research. World Med J. 1964;11:281. 
103. Rid A, Schmidt H. The 2008 Declaration of Helsinki - first among equals in research 
ethics? J Law Med Ethics. 2010;38 (1):143-8. 
152 
 
104. Basu K, Palmer CNA, Lipworth BJ, McLean WHI, Terron-Kwiatkowski A, Zhao Y, 
et al. Filaggrin Null Mutations Are Associated With Increased Asthma Exacerbations In 
Children And Young Adults. Allergy. 2008 Sep;63(9):1211-7. 
105. Basu K, Palmer CNA, Tavendale R, Lipworth BJ, Mukhopadhyay S. Adrenergic 
beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients 
taking frequent albuterol or salmeterol. J Allergy Clin Immunol. 2009 Dec;124(6):1188-94. 
e3. 
106. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir 
J. 2005; 26(2): 319-338 
107. Rosenthal M, Bain SH, Cramer D, Et al. Lung function in white children aged 4 to 19 
years: I—Spirometry. Thorax. 1993;48:794–802. 
108. Gilbert R, Auchincloss JHJ. The interpretation of the spirogram. How accurate is it for 
'obstruction'? Arch Intern Med. 1985;145(9):1635-9. 
109. Miteva M, Richter S, Elsner P, Fluhr JW. Approaches for optimizing the calibration 
standard of Tewameter TM 300. Exp Dermatol. 2006. ;15:904-12. 
110. Moskowitz DG, Fowler AJ, Heyman MB, Cohen SP, Crumrine D, Elias PM, et al. 
Pathophysiologic basis for growth failure in children with icthyosis: an evaluation of 
cutaneous ultrastructure, epidermal permeability barrier function, and energy expenditure. 
Journal of Pediatrics. 2004;145:82-92. 
111. Lee CH, Chuang HY, Shih CC, Jong SB, Chang CH, Yu HS. Transepidermal water 
loss, serum IgE and beta endorphin as important and independent biological markers for 
development of itch intensity in atopic dermatitis. . British Journal of Dermatology. 
2006;154:1100-7. 
153 
 
112. Fleming SC, Kapenbwa MS, Laker MF, Levin GE, Griffin GE. Rapid and 
simultaneous determination of lactulose and mannitol in urine, by HPLC with pulsed 
amperometric detection, for use in studies of intestinal permeability. Clinical Chemistry 
and Laboratory Medicine. 1990;36:797-9. 
113. Kynaston JA, Fleming SC, Laker MF, Pearson AD. Simultaneous quantification of 
mannitol, 3-O-methyl glucose, and lactulose in urine by HPLC with pulsed electrochemical 
detection, for use in studies of intestinal permeability. Clinical Chemistry and Laboratory 
Medicine 1993;39:453-6. 
114. Bieche I, Olivi M, Champeme MH, Vidaud D, Lidereau R, Vidaud M. Novel approach 
to quantitative polymerase chain reaction using real-time detection: application to the 
detection of gene amplification in breast cancer. International Journal of Cancer. 
1998;78(5):661-6. 
115. Timonen KL, Pekkanen J, Korppi M, Vahteristo M, Salonen RO. Prevalence and 
characteristics of children with chronic respiratory symptoms in eastern Finland. European 
Respiratory Journal. 1995;8:1155–60. 
116. Lee DK, Jackson CM, Currie GP, Cockburn WJ, Lipworth BJ. Comparison of 
combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. Br J 
Clin Pharmacol. 2003 Nov;56(5):494-500. 
117. Hall IP, Blakey JD, Al Balushi KA, Wheatley A, Sayers I, Pembrey ME, et al. Beta2-
adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 
birth cohort: a genetic association study. Lancet. 2006 Aug 26;368(9537):771-9. 
154 
 
118. Zuidgeest MG, Smit HA, Bracke M, Wijga AH, Brunekreef B, Hoekstra MO, et al. 
Persistence of asthma medication use in preschool children. Respir Med. 2008 Oct;102(10): 
1446-51 
119. A feat worth replicating. Nat Genet. 2005;37(4):329. 
120. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between 
Genetic Polymorphisms of the b2-Adrenoceptor and Response to Albuterol in Children 
with and without a History of Wheezing. Journal of Clinical Investigation. 1997;100:3184-
8. 
121. Taylor DA, Jensen MW, Aikman SL, Harris JG, Barnes PJ, O'Connor BJ. Comparison 
of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate 
and histamine in mild asthma. American Journal of Respiratory Critical Care Medicine. 
1997 Dec;156(6):1731-7. 
122. Currie GP, Lee DK, Haggart K, Bates CE, Lipworth BJ. Effects of montelukast on 
surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir 
Crit Care Med 2003 May 1;167(9):1232-8. 
123. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Eff 
ect of ADRB2 polymorphisms on response to longacting β2-agonist therapy: a 
pharmacogenetic analysis of two randomised studies. Lancet. 2007;370:2118-25. 
124. Korppi M, Kuikka L, Reijonen T, Remes K, Juntunen-Backman K, Launiala K. 
Bronchial asthma and hyperreactivity after early childhood bronchiolitis or pneumonia. An 
8-year follow-up study. Arch Pediatr Adolesc Med. 1994 Oct; 148 (10): 1079-84. 
125. Korppi M, Remes K. Asthma treatment in schoolchildren: lung function in different 
therapeutic groups. Acta Paediatr. 1996 Feb;85(2):190-4. 
155 
 
126. Mitra AD, Ogston S, Crighton A, Mukhopadhyay S. Lung function and asthma 
symptoms in children: relationships and response to treatment. Acta Paediatr. 
2002;91(7):789-92. 
127. Piippo-Savolainen E, Remes S, Kannisto S, Korhonen K, Korppi M. Early predictors 
for adult asthma and lung function abnormalities in infants hospitalized for bronchiolitis: a 
prospective 18- to 20-year follow-up. Allergy Asthma Proc. 2006 Jul-Aug;27(4):341-9. 
128. Wechsler M, Lehman E, Lazarus S, Lemanske R, Jr., Boushey H, Deykin A, et al. 
beta-Adrenergic receptor polymorphisms and response to salmeterol. American Journal of 
Respiratory Critical Care Medicine. 2006 Mar 1;173(5):519-26. 
129. Piippo-Savolainen E, Korppi M. Wheezy babies--wheezy adults? Review on long-
term outcome until adulthood after early childhood wheezing. Acta Paediatr. 2008 
Jan;97(1):5-11. 
130. Hyvärinen M, Piippo-Savolainen E, Korhonen K, Korppi M. Teenage asthma after 
severe infantile bronchiolitis or pneumonia. Acta Paediatrica. 2005 Oct;94(10):1378-83. 
131. Korppi M, Kuikka l, Reijonen T, Remes K, Juntunen-Backman K, Launiala K. 
Bronchial asthma and hyperreactivity after early childhood bronchiolitis or pneumonia. An 
8-year follow-up study. Arch Pediatr Adolesc Med 1994; 148:1079-84. 
132. Kotaniemi-Syrjänen A, Reijonen TM, Korhonen K, Korppi M. Wheezing requiring 
hospitalization in early childhood: predictive factors for asthma in a six-year follow-up. 
Pediatr Allergy Immunol. 2002 Dec;13(6):418-25. 
133. Stein RT, Holberg CJ, Sherrill D, Wright AL, Morgan WJ, Taussig L, et al. Influence 
of parental smoking on respiratory symptoms during the first decade of life: the Tucson 
Children's Respiratory Study. Am J Epidemiol.1999 Jun 1;149 (11): 1030-7. 
156 
 
134. O'Connor BJ, Aikman SL, Barnes PJ. Tolerance to the nonbronchodilator effects of 
inhaled beta 2-agonists in asthma. N Engl J Med. 1992 Oct;327(17):1204-8. 
135. Lerbaek A, Bisgaard H, Agner T, Ohm Kyvik K, Palmer CN, Menné T. Filaggrin null 
alleles are not associated with hand eczema or contact allergy. Br J Dermatol. 2007 
Dec;157(6):1199-204. 
136. Holgate ST. Exacerbations- The Asthma Paradox. Am J Respir Crit Care Med. 
2005;172:941-2. 
137. Johnston NW, Sears MR. Asthma exacerbations . 1: epidemiology. Thorax. 2006 
Aug;61(8):722-8. 
138. Johnston N, Johnston SL, Duncan JM, Greene JM, Kebadze T, Keith PK, et al. The 
September epidemic of asthma exacerbation in children: a search for etiology. J Allergy 
Clin. 2005;115:230-2. 
139. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, et al. 
Community study of role of viral infections in exacerbations of asthma in 9–11 year old 
children. Br Med J 1995;310:1225–8. 
140. Johnston SL, Pattemore PK, Sanderson G, Smith S, Campbell MJ, Josephs LK, et al. 
The relationship between upper respiratory infections and hospital admissions for asthma: a 
time trend analysis. Am J Respir Crit Care Med. 1996;154:654-60. 
141. Doull IJ, Lampe FC, Smith S, Schreiber J, Freezer NJ, Holgate ST. Effect of inhaled 
corticosteroids on episodes of wheezing associated with viral infection in school age 
children: randomised double blind placebo controlled trial. BMJ. 1997;31:858- 62. 
157 
 
142. Wilson NM, Silverman M. Treatment of acute, episodic asthma in preEditorials 943 
school children using intermittent high dose inhaled steroids at home. Arch Dis Child. 
1990;65:407- 10. 
143. Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, Debenedetto A, et al. 
Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin 
Immunol. 2007 Jul;120(1):150-5. 
144. van den Oord RAHM, Sheikh A. Filaggrin gene defects and risk of developing allergic 
sensitisation and allergic disorders: systematic review and meta analysis. British Medical 
Journal (Clinical Research Ed). 2009; 339. 
145. Hon KL, Wong KY, Leung TF, Chow CM, Ng PC. Comparison of skin hydration 
evaluation sites and correlations among skin hydration, transepidermal water loss, 
SCORAD index, Nottingham Eczema Severity Score, and quality of life in patients with 
atopic dermatitis. Am J Clin Dermatol. 2008; 9 (1):45-50. 
146. Davin JC, Pierard G, Dechenne C, Grossman D, Nagy J, Quacoe M, Malaise M, Hall 
M, Jansen F, Chantraine JM, et al. Possible pathogenic role of IgE in Henoch-Schönlein 
purpura. Pediatr Nephrol. 1994 Apr;8(2):169-71. 
147. Miraglia del Giudice M Jr, De Luca MG, Capristo C. Probiotics and atopic dermatitis. 
A new strategy in atopic dermatitis. Dig Liver Dis. 2002 Sep;34 Suppl 2:S68-71. 
148. Bian B, Kelton CM, Wigle PR, Guo JJ. Evaluating Safety of Long-Acting Beta 
Agonists (LABAs) in Patients with Asthma. . Curr Drug Saf 2010; Mar 7; [Epub ahead of 
print].  
149. Kramer JM. Balancing the benefits and risks of inhaled long-acting beta-agonists--the 
influence of values. . N Engl J Med. 2009 Apr 16;360(16):1592-5. 
158 
 
150. Reddel HK, Gibson PG, Peters MJ, Wark PA, Sand IB, Hoyos CM, et al. Down-
titration from high-dose combination therapy in asthma: Removal of long-acting β2-agonist  
2010 Respir Med. 2010. 
151. Menzies D, Nair A, Lipworth BJ. Portable exhaled nitric oxide measurement: 
Comparison with the "gold standard" technique. Chest. 2007 Feb.;131(2):410-4. 
152. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring 
quality of life in children with asthma. Quality of Life Research. 1996;5:35-46. 
153. Juniper EF, Guyatt GH, Feeny DH, Griffith LE, Ferrie PJ. Minimum skills required by 
children to complete health-related quality of life instruments for asthma: comparison of 
measurement properties. European Respiratory Journal. 1997;10:2285-94. 
154. Barnes PJ. effects of β2-agonists on inflammatory cells. J Allergy Clin Immunol. 1999, 
104:S10-S17 
155. Bhatnagar P, Guleria R, Kukreti R. Pharmacogenomics of beta2-agonist: key focus on 
signaling pathways. Pharmacogenomics. 2006 Sep; 7(6):919-33.) 
156. Marenholz I, Nickel R, Rüschendorf F, Schulz F, Esparza-Gordillo J, Kerscher T, 
Grüber C, Lau S, Worm M, Keil T, Kurek M, Zaluga E, Wahn U, Lee YA. Filaggrin loss-
of-function mutations predispose to phenotypes involved in the atopic march. J Allergy 
Clin Immunol. 2006 Oct;118(4):866-71. Epub 2006 Sep 1.) 
157. http://www.asthma.org.uk/news_media/media_resources/for_journalists_ key.html. 
2009 Last accessed October 18. 
158. Kamble S, Bharmal M. Incremental direct expenditure of treating asthma in the United 
States. J Asthma. 2009 Feb;46(1):73-80. 
159 
 
159. www.asthma.org.uk. Key facts, 2005. 
160. Lung report III British Lung Foundation 2003. 
161. Hedgecoe A M. Context, ethics and pharmacogenetics. Stud. Hist. Phil. Biol. & 
Biomed. Sci. 2006; 37: 566–582 
162. Beeson, D., & Dokusm, T. (2000). Family values and resistance to genetic testing. In 
B. Hoffmaster (Ed.),Bioethics in a social context (pp. 153–179). Philadelphia: Temple 
University Press. 
163. Bazell, R. (1998). Her-2: The making of Herceptin. a revolutionary treatment for 
breast cancer. Random House. 
164. McLeod, H. L., & Evans, W. E. (2001). Pharmacogenomics: Unlocking the human 
genome for better drug therapy. Annual Review of Pharmacology and Toxicology, 41, 
101–121. 
165. Lindpaintner, K. (1999). Genetics in drug discovery and development: Challenge and 
promise of individualizing treatment in common complex disease. British Medical Bulletin, 
55(2), 471–491. 
166. Wolf, C. R., Smith, G., & Smith, R. L. (2000). Pharmacogenetics. British Medical 
Journal, 320, 987–990. 
167. Permanand G, Mossialos E, McKee M. The EU's new paediatric medicines legislation: 
serving children's needs? Archives of Disease in Childhood 2007;92(9):808-811. 
168. Bousquet J. Global Initiative for Asthma (GINA) and its objectives. Clinical and 
Experimental Allergy 2000;30:2-5 
160 
 
169. Simar MR. Pediatric drug development: The International Conference on 
Harmonization focus on clinical investigations in children. Drug Information Journal 
2000;34(3):809-819. 
170. Medical Research Council. MRC Ethics Guide: Medical research involving children. 
2004. 
171. McIntosh N, Bates P, Brykczynska G, Dunstan G, Goldman A, Harvey D, et al. 
Guidelines for the ethical conduct of medical research involving children. Royal College of 
Paediatrics, Child Health: Ethics Advisory Committee. Arch Dis Child 2000;82(2):177-82. 
172. Harper PS, Clarke AJ. Genetics: Society and Clinical Practice. Oxford: Bios Scientific 
Publishers, 1997. 
173. Freund CL, Clayton EW. Pharmacogenomics and children: meeting the ethical 
challenges. American Journal Of Pharmacogenomics: Genomics-Related Research In Drug 
Development And Clinical Practice 2003;3(6):399-404. 
174. Henrikson NB, Burke W, Veenstra DL. Ancillary risk information and 
pharmacogenetic tests: social and policy implications. The Pharmacogenomics Journal 
2008;8(2):85. 
175. Hedgecoe A. Pharmacogenetics as alien science: Alzheimer's disease, core sets and 
expectations. Social Studies of Science 2006;36(5):723-752.  
176. Anderson, W. H., Fitzgerald, C. Q., & Monasco, P. K. (1999). Current and future 
applications of pharmacogenomics. New Horizons, 7(2), 262–269. 
177. Sadee, W. (1999). Pharmacogenomics. Western Journal of Medicine, 171(5/6), 328–
332. 
161 
 
178. Rioux, P. (2000). Clinical trials in pharmacogenetics and pharmacogenomics: 
Methods and applications. American Journal of Health System Pharmacy, 57(9), 887–898. 
179. Hedgecoe A, Martin P. (2003). The drugs don‘t work: Expectations and the shaping of 
pharmacogenetics. Social Studies of Science, 33(3), 327–364. 
180. Rothstein, M. A. (Ed.) (2003). Pharmacogenomics: Social, ethical and clinical 
dimensions. New Jersey: John Wiley & Sons. 
181. Buchanan, A., Califano, A., Kahn, J., McPherson, E., Robertson, J., & Brody, B. 
(2002). Pharmacogenetics: Ethical and regulatory issues in research and clinical practice. 
Report of the consortium on pharmacogenetics. Findings and recommendations. 
http://www.bioethics.umn.edu/News/pharm_report.pdf. 
182. Nuffield Council on Bioethics (2003). Pharmacogenetics: Ethical issues: Report of 
working party. London: Nuffield Council on Bioethics. 
183. Rothstein, M. A., & Epps, P. G. (2001). Ethical and legal implications of 
pharmacogenomics. Nature Reviews Genetics, 2, 228–231. 
184. Robertson, J. (2001). Consent and privacy in pharmacogenetic testing. Nature 
Genetics, 28(3), 207–209. 
185. Clarke, A., English, V., Harris, H., & Wells, F. (2001). Report on ethical 
considerations. International Journal of Pharmaceutical Medicine, 15, 89–94. 
186. Consortium on Pharmacogenetics (2002). Pharmacogenetics: Ethical and regulatory 
issues in research and clinical practice report, findings and recommendations. 
http://www.firstgenetic.net/latest_news/article_16.pdf. 
162 
 
187. Brushwood, D. B. (2003). The challenges of pharmacogenomics for pharmacy 
education, practice, and regulation. In M. A. Rothstein (Ed.), Pharmacogenomics: Social, 
ethical and clinical dimensions (pp. 207–225). New Jersey: John Wiley & Sons. 
188. Palmer, L. (2003). Medical liability for pharmacogenomics. In M. A. Rothstein (Ed.), 
Pharmacogenomics: Social, ethical and clinical dimensions (pp. 187–206). New Jersey: 
John Wiley & Sons. 
189. Levine, R. (1988). Ethics and regulation of clinical research (2nd ed.). New Haven: 
Yale University Press  
190. Smith, T. (1999). Ethics in medical research. Cambridge: Cambridge University Press. 
191. Beauchamp, T. L., & Childress, J. F. (2001). Principles of biomedical ethics (5th ed.). 
Oxford: Oxford University Press. 
192. Sugarman, J., McCrory, D. C., Powell, D., Krasny, A., Adams, B., Ball, E., & Cassell, 
C. (1999). Empirical research on informed consent. An annotated bibliography. The 
Hastings Center Report, 29(1), S1–S42. 
163 
 
APPENDIX 
 
 Publications from the work presented in the thesis 
 
1. Basu K, Palmer CNA, Tavendale R, Lipworth BJ, Mukhopadhyay S. Adrenergic 
β2-receptor genotype predisposes to exacerbations in asthmatics on as required 
albuterol and regular salmeterol.  J Allergy Clin Immunol.(Impact factor 9.773) 
2009 Dec;124(6):1188-94.e3. 
2. Basu K, Palmer CNA, Lipworth BJ, McLean WHI, Terron-Kwiatkowski A, Zhao 
Y, Liao H, Smith FJD, Mitra A, Mukhopadhyay S. Filaggrin null mutations are 
associated with increased asthma exacerbations in children and young adults. 
Allergy. (Impact factor 6.204) 2008 Sep; 63(9):1211-7.  
 
 Abstracts from the work presented in the thesis 
 
1. Basu K, Palmer CNA, Tavendale R, Lipworth BJ, Mukhopadhyay S. Adrenergic 
β2-receptor genotype predisposes to exacerbations in asthmatics on as required 
short acting and regular long acting β2 agonists. Oral presentation for the award of 
Runner up- Young Investigator at the British Thoracic Society winter meeting 
2008  
2. Basu K, Palmer CNA, Lipworth BJ, McLean WHI, Terron-Kwiatkowski A, Zhao 
Y, Liao H, Smith FJD, Mitra A, Mukhopadhyay S. Filaggrin Null Mutations May 
Predict Increased Risk Of Asthma Exacerbations In Children And Young Adults. 
164 
 
Oral presentation at the Royal College of Paediatrics and Child Health annual 
spring meeting 2008  
3. Basu K. The effect of gene variations on exacerbations and treatment preferences 
in children‘s asthma- Poster presented at the annual postgraduate symposium, 
University of Dundee- July 2008 
4. Basu K. The effect of β2 agonist receptor gene variation on treatment 
preferences in children‘s asthma- Oral presentation at the annual 
postgraduate symposium, University of Dundee- June 2007 
 
 
 
